Browse Trials
In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.
Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.
Currently viewing trials
(Last updated: August 03, 2020)
Close
Treatment
BRCA1/2
Chemotherapy
Hormone Therapy
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Non-Treatment
Activities
Complementary and Alternative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Screening
Support/Education
Surveys/Interviews/Registries
Click here to view online studies and trials that do not require site visits
1
NEAREST SITE: 3 miles
Quest Clinical Research
San Francisco,CA
VISITS: Weekly visits, ongoing
PHASE: I-II
NCT ID: NCT03838367
Leronlimab & Carboplatin for Metastatic Triple Negative Breast Cancer That Tests CCR5+
A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC) Scientific Title
Purpose
To determine the best dose, safety and effects (good and bad) of leronlimab when it is used along with carboplatin.
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer that the researchers find tests positive for CCR5 and not have been treated with chemotherapy or a checkpoint inhibitor for metastatic breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leronlimab (PRO 140), by injection, weekly </li> <li class="seamTextUnorderedListItem">Carboplatin, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leronlimab is an investigational targeted therapy that blocks CCR5. </li> <li class="seamTextUnorderedListItem">Carboplatin is a chemotherapy drug used to treat breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03838367' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.globenewswire.com/news-release/2019/05/07/1818129/0/en/FDA-Grants-CytoDyn-Fast-Track-Designation-for-Leronlimab-PRO-140-in-metastatic-Triple-Negative-Breast-Cancer-an-Unmet-Medical-Need.html' target='_blank'>Drug company information page: Leronlimab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/web-exclusives/fda-grants-fast-track-designation-to-leronlimab-for-metastatic-tnbc' target='_blank'>Onclive: Leronlimab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancercare.org.uk/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/carboplatin' target='_blank'>Breastcancer.org: Carboplatin</a> </li></ul>
2
NEAREST SITE: 3 miles
University of California San Francisco (UCSF)
San Francisco,CA
VISITS: 1 visit every 3 weeks, ongoing
PHASE: I-II
NCT ID: NCT03717415
Targeted Therapy Rebastinib With Carboplatin for Advanced Triple Negative Breast Cancer
An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors Scientific Title
Purpose
To study the safety, dose and effects (good and bad) of the targeted therapy rebastinib (DCC-2036) when used along with carboplatin (Paraplatin®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rebastinib (DCC-2036), by mouth, daily</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rebastinib targets a receptor called TIE2. Researchers believe blocking this protein will keep tumors from growing and spreading. </li> <li class="seamTextUnorderedListItem">Paraplatin is a chemotherapy drug routinely used to treat advanced and metastatic <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03717415' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rebastinib-tosylate' target='_blank'>NCI: rebastinib tosylate</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.deciphera.com/pipeline/rebastinib/' target='_blank'>Trial Sponsor (Deciphera): Rebastinib</a> </li><li class='seamTextUnorderedListItem'><a href='https://investors.deciphera.com/news-releases/news-release-details/deciphera-pharmaceuticals-reports-updated-preliminary-phase-1' target='_blank'>Trial Sponsor (Deciphera): Press release</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancercare.org.uk/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/carboplatin#who' target='_blank'>Breastcancercare.org.uk: Carboplatin</a> </li></ul>
3
NEAREST SITE: 3 miles
University of California, San Francisco
San Francisco,CA
VISITS: 1 visit every 2 weeks, ongoing
PHASE: II
NCT ID: NCT03971409
Avelumab With Binimetinib, Utomilumab, or PF-04518600 For Advanced Triple Negative & ER-Low Breast Cancer
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study (InCITe) Scientific Title
Purpose
To look at the safety and effects (good and bad) of combining the immunotherapy drug avelumab (Bavencio®) with binimetinib, utomilumab, or PF-04518600.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) or ER-Low (1%-10% ER) breast cancer who have not had more than three lines of chemotherapy and not more than one checkpoint inhibitor.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Binimetinib, by mouth, twice daily</li> <li class="seamTextUnorderedListItem">Avelumab (Bavencio®), by IV, every 2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-04518600, by IV, every 2 weeks </li> <li class="seamTextUnorderedListItem">Avelumab (Bavencio®), by IV, every 2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Utomilumab, by IV, once a month</li> <li class="seamTextUnorderedListItem">Avelumab (Bavencio®), by IV, every 2 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Bavencio is type of immunotherapy called a PD-L1 inhibitor. It has been approved to treat certain types of cancer. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Binimetinib (Mektovi®) is targeted therapy that blocks MEK, which helps cancer cells grow. It is used to treat metastatic melanoma. Its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">PF-04518600 is an investigational immunotherapy that targets OX40, a protein found on immune cells that have interacted with cancer cells. </li> <li class="seamTextUnorderedListItem">Utomilumab is an investigational immunotherapy that targets the 4-1BB (CD-137) protein on certain immune cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03971409' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/avelumab' target='_blank'>NCI Drug Dictionary: Avelumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://immuno-oncologynews.com/pf-04518600/' target='_blank'>Immuno-Oncology News: PF-04518600</a> </li><li class='seamTextUnorderedListItem'><a href='https://pfe-pfizercom-prod.s3.amazonaws.com/news/asco/Pfizer_IO_41BB_UtomilumabFactSheet.pdf' target='_blank'>Pfizer oncology: Utomilumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.arraybiopharma.com/our-science/our-pipeline/binimetinib' target='_blank'>Array Biopharma: BINIMETINIB</a> </li></ul>
4
NEAREST SITE: 3 miles
University of California San Francisco Medical Center
San Francisco,CA
VISITS: 4 visits over 2 months
PHASE: I
NCT ID: NCT03517488
XmAb20717 Immunotherapy for Advanced Triple Negative Breast Cancer
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Scientific Title
Purpose
To test the safety, effects (good and bad) and best dose of an experimental immunotherapy called XmAb20717.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) that has not responded to other treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XmAb20717, by IV, once every 2 weeks, for 2 months</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XmAb20717 blocks two proteins on immune cells, PD-1 and CTLA4. </li> <li class="seamTextUnorderedListItem">Blocking these proteins helps your immune system see and go after cancer cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03517488' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793410' target='_blank'>NCI drug dictionary: XmAb20717</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prnewswire.com/news-releases/xencor-doses-first-patient-in-phase-1-study-of-xmab20717-dual-checkpoint-inhibitor-for-the-treatment-of-advanced-solid-tumors-300680374.html' target='_blank'>Xencor press release: XmAb20717</a> </li></ul>
5
NEAREST SITE: 3 miles
UCSF Comprehensive Cancer Ctr
San Francisco,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03289962
Personalized Cancer Vaccine With or Without Atezolizumab for Advanced Triple Negative Breast Cancer
A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors Scientific Title
Purpose
To investigate the safety and effects (good and bad) of using a personalized cancer vaccine (RO7198457) alone or with an immunotherapy drug (the PD-LI inhibitor atezolizumab).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer. Your cancer must have progressed after receiving standard of care therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RO7198457, by IV, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RO7198457, by IV, ongoing</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The personalized cancer vaccine is called RO7198457. </li> <li class="seamTextUnorderedListItem">The immunotherapy being used in this study is the PD-L1 inhibitor atezolizumab (Tecentriq®). </li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) works by blocking the PD-L1 (programmed death-ligand 1) protein and is approved to treat certain types of cancer. Its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03289962' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tecentriq-hcp.com' target='_blank'>Genentech Information Page: Tecentriq</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=791183' target='_blank'>NCI Drug Dictionary: RO7198457</a> </li></ul>
6
NEAREST SITE: 3 miles
UCSF Medical Center
San Francisco,CA
VISITS: 1 visit every 3 weeks, ongoing
PHASE: I
NCT ID: NCT03454451
CPI-006 Alone or With CPI-444 or Keytruda in Advanced Triple Negative Breast Cancer
A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers Scientific Title
Purpose
To test the safety and effects (good and bad) of CPI-006 when it is given alone or with CPI-444 or with pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer that has not responded to other treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CPI-006, by IV, once every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CPI-006, by IV, once every 3 weeks</li> <li class="seamTextUnorderedListItem">CPI-444, by mouth, twice daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CPI-006, by IV, once every 3 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, once every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CPI-006 is an investigational immunotherapy that gets the immune system to after cancer cells by targeting CD73. </li> <li class="seamTextUnorderedListItem">CPI-444 is an investigational immunotherapy that targets the adenosine-A2A receptor (ADORA2A) on immune cells. </li> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy called a checkpoint inhibitor. It gets the immune system to go after cancer cells by blocking PD-1. </li> <li class="seamTextUnorderedListItem">Keytruda is approved to treat certain types of cancer. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03454451' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.2505' target='_blank'>Journal of Clinical Oncology: CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adenosine-a2a-receptor-antagonist-cpi-444' target='_blank'>NCI Drug Dictionary: adenosine-A2A receptor antagonist CPI-444</a> </li></ul>
7
NEAREST SITE: 3 miles
University of California -San Francisco
San Francisco,CA
VISITS: Weekly visits for 2 months, monthly visits thereafter
PHASE: II
NCT ID: NCT03519178
PF-06873600 for Metastatic HER2-Negative Breast Cancer
Phase 1/2a Dose Escalation And Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamics And Anti-tumor Activity Of Pf-06873600 As A Single Agent And In Combination With Endocrine Therapy Scientific Title
Purpose
To evaluate the safety and effects (good and bad) of PF-06873600, a new targeted therapy.
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or hormone receptor (ER+ and/or PR+) positive, HER2 negative (HER2-) breast cancer who have already received a CDK 4/6 inhibitor.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-06873600, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-06873600, by mouth</li> <li class="seamTextUnorderedListItem">Endocrine therapy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-06873600 is a cyclin-dependent kinase (CDK) inhibitor. </li> <li class="seamTextUnorderedListItem">It works by inhibiting the CDK enzymes that help cancer cells grow. </li> <li class="seamTextUnorderedListItem">Patients in the study with hormone-receptor positive breast cancer will also be treated with an anti-estrogen therapy.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03519178' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793673' target='_blank'>NCI Drug Dictionary: PF-06873600</a> </li></ul>
8
NEAREST SITE: 3 miles
University of California at San Francisco
San Francisco,CA
VISITS: 1 visit every 3 weeks, ongoing
PHASE: I
NCT ID: NCT01969643
SGN-LIV1A for Metastatic HER2 Negative Breast Cancer
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer Scientific Title
Purpose
To determine the safety, highest tolerable dose and anti-tumor activity of SGN-LIV1A.
Who is this for?
Women with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or HER2 negative (HER2-), hormone receptor positive (ER+ and/or PR+) breast cancer that can no longer be treated with a hormone therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following treatment: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-LIV1A, by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Antibody-drug conjugate (ADC) is a cancer therapy that combines an antibody that targets cancer cells with a drug that can kill cancer cells. </li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the drug does not kill normal cells, making it less likely to cause side effects. </li> <li class="seamTextUnorderedListItem">SGN-LIV1A is an ADC that targets LIV-1 (SLC39A6), a protein that is expressed by most breast cancer cells, and delivers a cancer drug called monomethyl auristatin E.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01969643' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.seattlegenetics.com/pipeline/sgn-liv1a' target='_blank'>Seattle Genetics Drug Information Page: SGN-LIV1A</a> </li></ul>
9
NEAREST SITE: 3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco,CA
VISITS: 2 visits every 3 weeks; or coincides with chemotherapy treatment
PHASE: III
NCT ID: NCT03901339
Sacituzumab Govitecan in Advanced Hormone Positive, HER2 Negative Breast Cancer (TROPICS-02)
Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens Scientific Title
Purpose
To compare the safety and effects (good and bad) of sacituzumab govitecan to standard of care chemotherapy.
Who is this for?
People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that has already been treated with 2 to 4 different chemotherapy regimens.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab Govitecan (IMMU-132), by IV, 2 times every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine), determined by your physician</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The investigational chemotherapy is called sacituzumab govitecan (IMMU-132). </li> <li class="seamTextUnorderedListItem">It is approved for use in some people with metastatic (stage IV) <span class="highlight">triple</span> <span class="highlight">negative</span> (ER-, PR-, HER2-) breast cancer.</li> <li class="seamTextUnorderedListItem">It is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy drug directly to these cells. </li> <li class="seamTextUnorderedListItem">The antibody in this drug targets TROP2 proteins. </li> <li class="seamTextUnorderedListItem">It delivers the chemotherapy drug SN-38.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03901339' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/latest-news/fda-approves-trodelvy-sacituzumab-govitecan-hziy-for-triple-negative-breast-cancer.html' target='_blank'>American Cancer Society: FDA Approves Trodelvy (Sacituzumab Govitecan-Hziy) for Triple Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/05/01/mbc-news-11/' target='_blank'>MetastaticTrialTalk: Getting to the Target, Antibody Drug Conjugates in Breast Cancer</a> </li></ul>
10
NEAREST SITE: 3 miles
UCSF Helen Diller Family CCC
San Francisco,CA
VISITS: 1-2 visits a month, ongoing
PHASE: I-II
NCT ID: NCT03280563
Immunotherapies, Targeted Therapies, and Anti-Estrogen Therapies for Advanced Hormone Positive, HER2 Negative Breast Cancer
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer) Scientific Title
Purpose
To evaluate the safety, effects (good and bad), and anti-cancer activity of several therapy combinations that include immunotherapies, targeted therapies, and anti-estrogen therapies.
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (ER+, HER2-) breast cancer. Your cancer must have recurred or progressed on your most recent treatment.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 7 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 1-2 times a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, once a month, ongoing</li> <li class="seamTextUnorderedListItem">Entinostat, by mouth, once a week, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 1-2 times a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, daily (3 weeks on, 1 week off), ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 5</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, daily (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 1-2 times a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 6</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) by injection or tamoxifen (Nolvadex®) or exemestane (Aromasin®) by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 7</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, twice a day, ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 1-2 times a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">If your disease progresses while on treatment, you may be eligible to receive a new combination treatment.</i> </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsies may be required</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 checkpoint inhibitor. It is approved to treat locally advanced or metastatic <span class="highlight">triple</span>-<span class="highlight">negative</span>, PD-L1-positive breast cancer.</li> <li class="seamTextUnorderedListItem">Entinostat is an investigational type of targeted therapy called an HDAC inhibitor.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068) is a new type of cancer drug that works by blocking the Akt protein</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin) is a monoclonal antibody that keeps tumors from growing by shrinking their supplying blood vessels. Avastin is used to treat HER2-negative metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a CDK 4/6 inhibitor that is commonly used to treat metastatic, hormone positive (ER+ and/or PR+) breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03280563' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.biooncology.com/pipeline-molecules/ipatasertib.html' target='_blank'>Genentech Drug Information Page: Ipatasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.gene.com/patients/medicines/tecentriq' target='_blank'>Genentech Drug Information Page: Tecentriq</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/hormone-therapy/fulvestrant-faslodex' target='_blank'>Breast Cancer Now: Fulvestrant</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/entinostat' target='_blank'>NCI Drug Dictionary: Entinostat</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/avastin' target='_blank'>Breastcancer.org: Avastin</a> </li></ul>
11
NEAREST SITE: 3 miles
University of California San Francisco ( Site 0007)
San Francisco,CA
VISITS: Weekly visits for 6 weeks, then 1 visit every 3 weeks, for up to 2 years
PHASE: I
NCT ID: NCT03010176
MK-1454 and Keytruda for Patients With Advanced Breast Cancer
Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas Scientific Title
Purpose
To determine the best dose and safety of a new immunotherapy drug, MK-1454.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer who have a tumor that has not responded to, or has stopped responding to, other treatments.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MK-1454, by IV, once a week for 6 weeks, then once every 3 weeks for 2 years </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, once every 3 weeks for 2 years </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MK-1454 is an immunotherapy drug that earlier studies suggest may make tumors more likely to respond to pembrolizumab (Keytruda®). </li> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy called a PD-1 inhibitor. It gets the immune system to go after cancer cells. </li> <li class="seamTextUnorderedListItem">Keytruda is approved to treat certain types of cancer, but not breast cancer. </li> <li class="seamTextUnorderedListItem">This study also is enrolling patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03010176' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://lymphomanewstoday.com/2018/11/05/mk-1454-keytruda-combo-shows-promise-interim-phase-1-data-shows/' target='_blank'>Lymphoma Today: MK-1454/Keytruda Combination Shows Promise in Solid Tumor and Lymphoma Patients</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.biopharmadive.com/news/esmo-2018-bavencio-pfizer-rcc-merck-sting-novartis-alpelisib/540263/' target='_blank'>BioPharmadive: ESMO 2018</a> </li></ul>
12
NEAREST SITE: 27 miles
Exelixis Clinical Site #21
Stanford,CA
VISITS: 1 visit every 3 weeks, ongoing
PHASE: I-II
NCT ID: NCT03170960
Cabozantinib Alone or With Atezolizumab in Advanced Triple Negative Breast Cancer
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Scientific Title
Purpose
To assess the safety, best dose, and effects (good and bad) of cabozantinib (Cabometyx®) when it is used alone or with atezolizumab (Tecentriq®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) that has already been treated with at least one line of therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, once every 3 weeks</li> <li class="seamTextUnorderedListItem">Cabozantinib (Cabometyx®), by mouth, daily</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cabometyx is a targeted therapy that blocks some of the signals that tell cancer cells to grow and divide and that stimulate the blood vessels the cancer cells need grow. It is approved to treat kidney and liver cancer. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Tecentriq is a type of immunotherapy called an immune checkpoint inhibitor. It is approved for use in combination with the chemotherapy drug Abraxane® (nab-paclitaxel) to treat advanced <span class="highlight">triple</span>-<span class="highlight">negative</span>, PD-L1-positive breast cancer. </li> <li class="seamTextUnorderedListItem">This study also is enrolling patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03170960' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a616037.html' target='_blank'>Medlineplus: Cabozantinib</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.1026' target='_blank'>ASCOPubs.org: A phase II study of cabozantinib alone or in combination with trastuzumab in patients with breast cancer brain metastases</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2019/atezolizumab-triple-negative-breast-cancer-fda-approval' target='_blank'>NCI: Atezolizumab Approved for Some Patients with TNBC</a> </li></ul>
13
NEAREST SITE: 27 miles
Stanford Cancer Center
Stanford,CA
VISITS: 3 visits a month, ongoing
PHASE: III
NCT ID: NCT04177108
Paclitaxel Alone or With Ipatasertib and/or Atezolizumab for People with Advanced TNBC
A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer. Scientific Title
Purpose
To look at at the safety and effects (good and bad) of the experimental targeted therapy ipatasertib (GDC-0068) when it is used along with the chemotherapy drug paclitaxel (Taxol®) and the immunotherapy atezolizumab (Tecentriq®).
Who is this for?
People who are starting treatment for advanced (some stage III) or metastatic (stage IV) triple negative breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> If your tumor is negative for PD-L1, you will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Placebo, by mouth, daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off)</li> </ul> <p class="seamTextPara"> If your tumor is positive for PD-L1, you will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Placebo, by mouth, daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ipatasertib is a type of targeted therapy called an AKT inhibitor. AKT is a protein that helps cancers grow.</li> <li class="seamTextUnorderedListItem">Tecentriq® is a type of immunotherapy called a PD-L1 (programmed death-ligand 1) inhibitor. It is approved for use along with Taxol to treat metastatic <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer that tests positive for PD-L1.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04177108' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://blog.dana-farber.org/insight/2017/05/what-is-a-pd-l1-test/' target='_blank'>Dana-Farber Cancer Institute: What is PD-L1?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2019/atezolizumab-triple-negative-breast-cancer-fda-approval' target='_blank'>NCI Cancer Currents Blog: Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.biooncology.com/pipeline-molecules/ipatasertib.html' target='_blank'>Genentech Information Page: Ipatasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/taxol-better-than-ixempra-or-abraxane' target='_blank'>Breastcancer.org: Study Confirms Taxol Better Than Ixempra or Abraxane for Locally Advanced or Metastatic Disease</a> </li></ul>
14
NEAREST SITE: 27 miles
Stanford University /ID# 206949
Stanford,CA
VISITS: 1 visit every 2 or 4 weeks, ongoing
PHASE: I
NCT ID: NCT03071757
ABBV-36 and ABBV-181 in Advanced Triple Negative Breast (and other) Cancers
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Scientific Title
Purpose
To study the safety and best dose of the investigational drug ABBV-368 when it is given with or without the investigational drug ABBV-181.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer and have already had a treatment that your cancer did not respond to or has stopped responding to.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-368, by IV, every 2 or 4 weeks, ongoing </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-368, by IV, every 4 weeks, ongoing</li> <li class="seamTextUnorderedListItem">ABBV-181, by IV</li> <li class="seamTextUnorderedListItem">18F PET scan</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-368 is an anti-OX40 monoclonal antibody that targets a protein found on some T cells. By targeting these proteins, the researchers think the drug will help other T cells kill cancer cells. </li> <li class="seamTextUnorderedListItem">ABBV-181 is a new type of PD-1 inhibitor. These are immunotherapy drugs that get the immune system to kill cancer cells by blocking PD-1. </li> <li class="seamTextUnorderedListItem">The study will also see if a new type of PET scan dye can help researchers see whether the drugs are activating an immune response. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03071757' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.abbvie.com/our-science/pipeline/abbv-368.html' target='_blank'>Drug Company Information Page: ABBV-368</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/targeted-cancer-drugs/types/monoclonal-antibodies' target='_blank'>Cancer Research UK: Monoclonal Antibodies</a> </li><li class='seamTextUnorderedListItem'><a href='https://immuno-oncologynews.com/abbv-181/' target='_blank'>Immuno-Oncology News: ABBV-181</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792559' target='_blank'>NCI Drug Dictionary: ABBV-368</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.6050' target='_blank'>ASCO Abstract: Novel PET imaging with [18F]F-AraG</a> </li></ul>
15
NEAREST SITE: 27 miles
Stanford University Hospitals and Clinics
Stanford,CA
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT02401347
Talazoparib for Advanced HER2 Negative Breast Cancer with Certain Mutations
A Phase II Clinical Trial of BMN 673 in BRCA1 and BRCA2 Wild-Type Patients With (i) Advanced Triple-Negative Breast Cancer and Homologous Recombination Deficiency as Assessed by the HRD Assay, and (ii) Advanced HER2-Negative Breast Cancer With Either a Germline or Somatic Mutation in... Scientific Title
Purpose
To study the safety and anti-cancer activity of the PARP inhibitor talazoparib (Talzenna®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that is HER2 negative (HER2-) and who have received at least one prior chemotherapy for metastatic disease. Your tumor must test positive for or express one of several markers. (See below for a list of targets and mutations.) You cannot enroll in this trial if you have an inherited BRCA 1 or BRCA 2 mutation.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, daily</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®) is a PARP inhibitor that is approved to treat people with advanced or metastatic HER2 negative (HER2-) breast cancer and an inherited BRCA 1 or BRCA 2 mutation. </li> <li class="seamTextUnorderedListItem">You cannot enroll in this trial If you have an inherited BRCA 1 or BRCA 2 mutation.</li> <li class="seamTextUnorderedListItem">Targets or mutations: Homologous Recombination Deficiency, PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, Rad51c, Rad51d, MRE11, ATR, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, plus other HR-related genes at the discretion of the primary investigators.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02401347' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/EmergingMetasticBreastCancer.html' target='_blank'>Susan G. Komen: Emerging Areas in Metastatic Breast Cancer Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.talzenna.com' target='_blank'>Pfizer Oncology Information Page: Talazoparib</a> </li></ul>
16
NEAREST SITE: 28 miles
Stanford Cancer Center
Palo Alto,CA
VISITS: 1 visit every 3 weeks, ongoing
PHASE: I
NCT ID: NCT03621982
ADCT-301 in Patients With Advanced Triple Negative Breast Cancer
A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors Scientific Title
Purpose
To compare the safety and effects (good and bad) of ADCT-301, a targeted therapy that combines the monoclonal antibody HuMax®-TACâ„¢ with a new type of chemotherapy drug called PBD.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer that has not responded to other treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ADCT-301, by IV, once every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ADCT-301 is a new type of targeted therapy that combines the monoclonal antibody HuMax®-TACâ„¢ with a new type of chemotherapy drug called PBD. </li> <li class="seamTextUnorderedListItem">The monoclonal antibody brings the chemotherapy directly to the cancer cells. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of advanced cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03621982' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://adcreview.com/editorial/adct-301-a-novel-antibody-drug-conjugate-against-lymphomas-moves-into-phase-i-clinical-trial/' target='_blank'>ADC Review: ADCT-301</a> </li></ul>
17
NEAREST SITE: 53 miles
St. Joseph Heritage Healthcare ( Site 0104)
Santa Rosa,CA
VISITS: At least 3 visits a month, ongoing
PHASE: II-III
NCT ID: NCT04191135
Two Chemotherapies Plus Immunotherapy With or Without A Targeted Therapy for Advanced Triple Negative Breast Cancer
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009) Scientific Title
Purpose
To study the anti-cancer activity and effects (good and bad) of adding the targeted therapy olaparib (Lynparza®) to the treatment combination of carboplatin (Paraplatin®), gemcitabine (Gemzar®), and the immunotherapy pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have not started treatment.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, weekly (2 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®), by IV, weekly (2 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, once every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, weekly (2 weeks on, 1 week off), for 3 to 5 months</li> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®), by IV, weekly (2 weeks on, 1 week off), for 3 to 5 months</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, once every 3 weeks, for 3 to 5 months</li> </ul> <p class="seamTextPara"> Then you will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, weekly (2 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a PARP inhibitor. It stops the growth of cancer cells by blocking enzymes called poly ADP ribose polymerase (PARP). </li> <li class="seamTextUnorderedListItem">It is approved to treat HER2-negative metastatic breast cancer in women with a hereditary BRCA genetic mutation. </li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®) is a chemotherapy drug routinely used to treat advanced and metastatic <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer. </li> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®)is a chemotherapy drug used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. It is approved to treat certain types of cancers. Its use in breast cancer is considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04191135' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lynparza.com/breast-cancer/breast-cancer-types/triple-negative.html' target='_blank'>AstraZeneca Information Page: Lynparza® (Olaparib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/carboplatin' target='_blank'>Breast Cancer Now: Carboplatin</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Gemcitabine' target='_blank'>Wikipedia: Gemcitabine</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com' target='_blank'>Merck Oncology: Keytruda®</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.curetoday.com/publications/cure/2019/immunotherapy-2019/breast-cancer-gets-a-boost-from-immunotherapy' target='_blank'>Cure Today: Breast Cancer Gets a Boost From Immunotherapy</a> </li></ul>
18
NEAREST SITE: 53 miles
St. Joseph Heritage Healthcare
Santa Rosa,CA
VISITS: 1 visit every 3 weeks, for 2 years
PHASE: I-II
NCT ID: NCT03761914
Immunotherapy Galinpepimut-S and Pembrolizumab for Advanced Triple Negative Breast Cancer
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers Scientific Title
Purpose
To assess the safety, effects (good and bad) and best dose of the immunotherapy galinpepimut-S when it is used along with pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer that has not responded to other treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be given the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GM-CSF, by injection, before Galinpepimut-S</li> <li class="seamTextUnorderedListItem">Galinpepimut-S, by injection, every 3 weeks, for up to 2 years</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, for 2 years</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Galinpepimut-S is a vaccine that targets the protein WT1. </li> <li class="seamTextUnorderedListItem">Higher than normal amounts of this protein are found on the surface of breast and certain other cancer cells. </li> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy called a PD-1 inhibitor. It is approved to treat certain types of cancer. Its use in breast cancer is considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03761914' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sellaslifesciences.com/galinpepimut-s-gps-therapy/' target='_blank'>Trial Sponsor Sellas Lifescience: Galinpepimut-S Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://immuno-oncologynews.com/galinpepimut-s/' target='_blank'>Immuno-Oncology News: Galinpepimut-S</a> </li><li class='seamTextUnorderedListItem'><a href='https://pharmaphorum.com/views-and-analysis/asco-2017-breast-cancer-keytruda/' target='_blank'>Pharmaphorum: ASCO 2017: Breast cancer next target for Keytruda</a> </li></ul>
19
NEAREST SITE: 74 miles
University of California Davis Comprehensive Cancer Center
Sacramento,CA
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT02498613
Cediranib and Lynparza for Metastatic Triple Negative Breast Cancer
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Scientific Title
Purpose
To study the effects (good and bad) and the anti-cancer activity of combining the PARP inhibitor olaparib (Lynparza®) with the targeted therapy cediranib.
Who is this for?
People with advanced (stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer. You must have received one prior therapy for your cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cediranib, by mouth, daily</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. </li> <li class="seamTextUnorderedListItem">Cediranib is a type of drug called an angiogenesis inhibitor. </li> <li class="seamTextUnorderedListItem">Giving cediranib with olaparib may make the olaparib more effective.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02498613' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.medscape.com/viewarticle/891245' target='_blank'>Medscape: Olaparib</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Cediranib' target='_blank'>Wikipedia: Cediranib</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
20
NEAREST SITE: 74 miles
University of California Davis Comprehensive Cancer Center
Sacramento,CA
VISITS: 1 visit every 3 weeks
PHASE: II
NCT ID: NCT02849496
Olaparib Alone or With Atezolizumab for People With Advanced HER2 Negative Breast Cancer & An Inherited BRCA1/2 Mutation
A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC) Scientific Title
Purpose
To compare the anti-cancer activity of the targeted therapy olaparib (Lynparza®) when it is given alone to when it is given in combination with the immunotherapy atezolizumab (Tecentriq®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 negative breast cancer who have an inherited BRCA 1 or BRCA 2 mutation.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily, ongoing</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsies</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA.</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is approved to treat HER2 negative (HER2-) metastatic breast cancer in women with a BRCA 1/2 genetic mutation.</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-LI inhibitor. It works by getting the immune system to go after cancer cells by blocking a protein called PD-L1 (programmed death ligand-1). </li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is approved for use in advanced <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer. Its use in this trial is considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02849496' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lynparza.com' target='_blank'>AstraZeneca Drug Information Page: Lynparza® (Olaparib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-breast-cancer-treatment/parp-inhibitors-in-breast-cancer-treatment' target='_blank'>Breast Cancer Now: PARP Inhibitors in Breast Cancer Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tecentriq.com' target='_blank'>Genentech Drug Information Page: Tecentriq® (Atezolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy' target='_blank'>Breastcancer.org: Immunotherapy</a> </li></ul>
21
NEAREST SITE: 74 miles
University of California Davis Comprehensive Cancer Center ( Site 0005)
Sacramento,CA
VISITS: 1 visit every 3 weeks, for 2 years
PHASE: II
NCT ID: NCT03797326
Pembrolizumab with Lenvatinib in Previously Treated Advanced Triple Negative Breast Cancer
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005) Scientific Title
Purpose
To evaluate the safety and effects (good and bad) of using pembrolizumab (Keytruda®) along with lenvatinib (Lenvima®).
Who is this for?
People with triple negative (ER-, PR-, HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer who have already had one or two treatment regimens.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, for 2 years </li> <li class="seamTextUnorderedListItem">Lenvatinib (Lenvima®), by mouth, daily</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy called a PD-1 inhibitor. </li> <li class="seamTextUnorderedListItem">It stimulates the body's immune system to go after cancer cells. </li> <li class="seamTextUnorderedListItem">It is approved to treat certain types of cancers, but its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Lenvima is a targeted therapy that blocks vascular endothelial growth factor receptor 2 (VEGFR2). </li> <li class="seamTextUnorderedListItem">It is approved for treating patients with certain types of thyroid, kidney and liver cancers. </li> <li class="seamTextUnorderedListItem">Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This study will also include people with other types of cancers.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03797326' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab' target='_blank'>NCI drug dictionary: Pembrolizumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/lenvatinibmesylate' target='_blank'>NCI drug dictionary: Lenvatinib</a> </li></ul>
22
NEAREST SITE: 86 miles
Pacific Cancer Care
Monterey,CA
VISITS: 3 visits per month, ongoing
PHASE: II
NCT ID: NCT03961698
IPI-549, Tecentriq® and Abraxane® for Advanced Triple-Negative Breast Cancer
A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination With Front-line Treatment Regimens in Patients With Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma Scientific Title
Purpose
To study the effects of IP-549 when it is used with atezolizumab (Tecentriq®) and paclitaxel (Abraxane®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple-negative (ER-,PR-,HER2-) breast cancer that has not been treated with chemotherapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IPI-549, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 2 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®), by IV, weekly, 3 weeks on, 1 week off, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IP-549 is a type of experimental targeted therapy called a PI3K-gamma inhibitor. </li> <li class="seamTextUnorderedListItem">Tecentriq is a type of immunotherapy called a PD-L1 checkpoint inhibitor. It is approved to treat locally advanced or metastatic <span class="highlight">triple</span>-<span class="highlight">negative</span>, PD-L1-positive breast cancer. </li> <li class="seamTextUnorderedListItem">Abraxane is a chemotherapy drug used to treat advanced breast cancer. </li> <li class="seamTextUnorderedListItem">This study also is enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03961698' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.infi.com/home/our-development-program/ipi-549/' target='_blank'>Drug Company Information Page: IPI-549</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tecentriq.com/sclc.html?c=pdl-16d97f8fb9c&gclid=Cj0KCQiAtrnuBRDXARIsABiN-7Ap43URSS2rpiy3bh9KrbUqV-3pLCuvw7edYCY1v2MKoHoTdD369TUaArAsEALw_wcB&gclsrc=aw.ds' target='_blank'>Genentech Information Page: Tecentriq®</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.abraxane.com' target='_blank'>Drug Company Information Page: Abraxane®</a> </li></ul>
23
NEAREST SITE: 336 miles
Ronald Reagan UCLA Medical Center
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03674827
A Vaccine-Based Immunotherapy For Stage IV Triple Negative Breast Cancer
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of Escalating Doses And Treatment Intensification Of A Vaccine-based Immunotherapy Regimen-2 (Vbir-2) (Pf-06936308) For Advanced Non-small Cell Lung Cancer And Metastatic Triple-negative Breast Cancer Scientific Title
Purpose
To investigate the safety and effects (good and bad) of increasing doses of a vaccine-based immunotherapy called TPF-06936308.
Who is this for?
People with metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-06936308, 4 times every 4 months</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The vaccine (TPF-06936308) is designed to make immune cells find and then stop the growth of cancer cells. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with advanced non-small cell lung cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03674827' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795350' target='_blank'>Cancer.gov: Adenoviral cancer vaccine PF-06936308</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/navigating-cancer-care/how-cancer-treated/immunotherapy-and-vaccines/what-are-cancer-vaccines' target='_blank'>Cancer.net: What are Cancer Vaccines?</a> </li></ul>
24
NEAREST SITE: 336 miles
Research Site
Los Angeles,CA
VISITS: 1 visit every 3 weeks, ongoing
PHASE: I
NCT ID: NCT03256344
Immunotherapy With Tecentriq for TNBC With Liver Metastases
A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases Scientific Title
Purpose
To evaluate the safety and effects of injecting the cancer drugs talimogene laherparepvec (Imlygic®) and atezolizumab (Tecentriq®) directly into the liver to treat liver metastases.
Who is this for?
People with metastatic (stage IV) triple negative (ER-/PR-/HER2-) breast cancer that has spread to the liver.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talimogene laherparepve (Imlygic® or T-VEC), by injection, every 3 weeks, for up to 9 months</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imlygic is an immunotherapy approved to treat advanced melanoma. It is injected directly into the melanoma tumors. </li> <li class="seamTextUnorderedListItem">Tecentriq is a type of immunotherapy called a PD-L1 inhibitor. It is approved to treat metastatic <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling patients who have colorectal cancer that has spread to the liver.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03256344' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://chemocare.com/chemotherapy/drug-info/talimogene-laherparepvec.aspx' target='_blank'>ChemoCare: Talimogene Laherparepvec</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a616006.html' target='_blank'>MedLine Plus: Talimogene Laherparepvec</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/news/tvec-injections-safe-in-patients-with-advancedstage-liver-metastases' target='_blank'>Targeted Oncology News: T-VEC Injections Safe in Patients with Advanced-Stage Liver Metastases</a> </li></ul>
25
NEAREST SITE: 336 miles
University of California, Los Angeles
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03401385
DS-1062a in Advanced Triple Negative Breast Cancer
Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors Scientific Title
Purpose
To study the safety, best dose, and effects (good and bad) of DS-1062a.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have no standard treatment options available.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DS-1062a</li> <li class="seamTextUnorderedListItem">2 biopsies</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DS-1062a is an investigational antibody-drug conjugate (ADC). This type of drug uses an antibody that targets cancer cells to deliver a chemotherapy drug directly to these cells.</li> <li class="seamTextUnorderedListItem">The antibody in this drug targets Trop-2 proteins. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced solid tumors.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03401385' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793720' target='_blank'>NCI Drug Dictionary: DS-1062a</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/05/01/mbc-news-11/' target='_blank'>Metastatic Trial Talk: Getting to the Target, Antibody Drug Conjugates in Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
26
NEAREST SITE: 336 miles
UCLA Hematology & Oncology Clinic
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03849469
XmAb®22841 and Pembrolizumab in Advanced Triple Negative Breast Cancer
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4) Scientific Title
Purpose
To determine the best dose, safety and effects of XmAb22841 when it is used alone or in combination with pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XmAb®22841</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XmAb®22841</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XmAb22841 is a new type of immunotherapy that targets CTLA-4 and LAG-3. </li> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy called a PD-1 inhibitor. It is approved to certain types of cancers. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancers.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03849469' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.xencor.com/pipeline/' target='_blank'>Drug company information page: XmAb®22841</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/latest-news/fda-approves-keytruda-pembrolizumab-for-any-tumor-with-specific-genetic-change.html' target='_blank'>Cancer.org: FDA Approves Keytruda (Pembrolizumab) for Any Tumor with Specific Genetic Change</a> </li></ul>
27
NEAREST SITE: 336 miles
University of California, Los Angeles
Los Angeles,CA
VISITS: Weekly visits for 6 weeks, then 1 visit every 3 weeks for 2 years
PHASE: I
NCT ID: NCT03719326
Immunotherapy Plus Chemotherapy for Advanced Triple Negative Breast Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast and Gynecologic Malignancies Scientific Title
Purpose
To evaluate the best dose, safety and effects (good and bad) of AB928 when it is used along with pegylated liposomal doxorubicin (PLD).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer that has progressed on or not responded to available therapies.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AB928, by injection, once a week for 6 weeks, then once every 3 weeks for 2 years </li> <li class="seamTextUnorderedListItem">Pegylated liposomal doxorubicin (DOXIL®), by IV, once every 3 weeks for 2 years</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AB928 is a targeted therapy that researchers think can boost the immune system.</li> <li class="seamTextUnorderedListItem">Pegylated liposomal doxorubicin (Doxil®) is a chemotherapy drug used to treat breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03719326' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.oncolink.org/cancer-treatment/oncolink-rx/doxorubicin-liposomal-doxil-r' target='_blank'>OncoLink: Doxorubicin Liposomal (Doxil®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.arcusbio.com/pipeline/ab928/' target='_blank'>Arcus: AB928</a> </li></ul>
28
NEAREST SITE: 336 miles
Ronald Reagan UCLA Medical Center
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT02554812
Using Two Immunotherapy Drugs to Treat Metastatic Triple Negative Breast Cancer
A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies Scientific Title
Purpose
To study the safety of avelumab and determine the best dose of it to use along with PF-05082566.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Avelumab plus PF-05082566 (schedule determined by the physician)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Using two immunotherapy drugs together may kill more cancer cells than using one alone. </li> <li class="seamTextUnorderedListItem">Avelumab and PF-05082566 are two new immunotherapy drugs now in clinical trials. </li> <li class="seamTextUnorderedListItem">Both work by blocking a protein called PD-L1. </li> <li class="seamTextUnorderedListItem">Blocking this protein allows the immune system to find and kill cancer cells. </li> <li class="seamTextUnorderedListItem">Some of these patients will receive the immunotherapy drug PF-04518600 along with avelumab.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02554812' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/ct2/show/NCT02554812?term=NCT02554812&rank=1' target='_blank'>ClinicalTrials.gov: Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.pfizer.com/news/press-release/press-release-detail/asco_2016_pivotal_avelumab_study_shows_positive_results_in_metastatic_merkel_cell_carcinoma' target='_blank'>Pfizer: Avelumab Study</a> </li></ul>
29
NEAREST SITE: 338 miles
Research Site
Santa Monica,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT04293094
AMG 650 for People With Advanced Triple Negative Breast Cancer
A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors Scientific Title
Purpose
To study the safety, effects (good and bad), and best dose of the experimental drug AMG 650.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have had at least one chemotherapy for advanced or metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <p class="seamTextPara"> AMG 650, by mouth, ongoing</p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of solid tumors.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04293094' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
30
NEAREST SITE: 339 miles
The Angeles Clinic and Research Center
Los Angeles,CA
VISITS: 1 visit every 2 or 4 weeks
PHASE: I
NCT ID: NCT03538028
Immunotherapy INCAGN02385 in Advanced Triple Negative Breast Cancer
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies Scientific Title
Purpose
To test the safety and effects (good and bad) of a new type of immunotherapy called INCAGN02385.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) that has not responded to other treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NCAGN02385, by IV, once every 2 or 4 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The immunotherapy, INCAGN02385, gets the immune system to see and go after cancer cells by activating a molecule found on T cells called LAG-3. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03538028' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://cancerres.aacrjournals.org/content/78/13_Supplement/3819' target='_blank'>Cancer Research Abstract: INCAGN02385</a> </li></ul>
31
NEAREST SITE: 339 miles
University of California, Los Angeles JCCC Clinical Research Unit
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT03674567
Immunotherapy for Advanced Triple Negative Breast Cancer
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer Scientific Title
Purpose
To look at the best dose, safety and effects (good and bad) of using FLX475 alone or with pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FLX475, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FLX475, by mouth</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FLX475 is an investigational targeted therapy that helps the immune system go after cancer cells. </li> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy called a PD-1 inhibitor. It is approved to treat certain types of cancers. Its use in breast cancer is considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03674567' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.flxbio.com/next-generation-immune-modulators/flx475/' target='_blank'>Sponsor site: FLX475</a> </li></ul>
32
NEAREST SITE: 339 miles
The Angeles Clinic and Research Institute
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT03665285
NC318 for Advanced Triple-Negative Breast Cancer
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Scientific Title
Purpose
To study the best dose, safety, and effects (good and bad) of an experimental cancer drug called NC318.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple-negative (ER-, PR-, HER2-) breast cancer that has low levels of the protein PD-L1 and have no standard treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NC318, by injection</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i> </p> <p class="seamTextPara"> <u>Additional procedures</u> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 or 2 biopsies</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NC318 is designed to block a protein, called S15, that keeps the immune system from killing cancer cells. </li> <li class="seamTextUnorderedListItem">Blocking this protein could help the immune system see and go after cancer cells. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03665285' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/796496' target='_blank'>NCI Drug Dictionary: NC318</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.nextcure.com/pipeline/' target='_blank'>Drug Company Information Page: NC318</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-20047808' target='_blank'>Mayo Clinic: Monoclonal Antibody Drugs for Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://blog.dana-farber.org/insight/2018/03/monoclonal-antibody-therapy-cancer/' target='_blank'>Dana-Farber Cancer Institute: What is Monoclonal Antibody Therapy for Cancer?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/keytruda-faq/what-are-pd1-and-pdl1/' target='_blank'>Merk Oncology: What are PD-1 and PD-L1?</a> </li></ul>
33
NEAREST SITE: 339 miles
UCLA School of Medicine
Los Angeles,CA
VISITS: Number of visits unavailable, ongoing
PHASE: I
NCT ID: NCT01351103
LGK974 and PDR001 for Advanced Triple Negative Breast Cancer
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands Scientific Title
Purpose
To study the best dose and effects (good and bad) of using the experimental targeted therapy LGK974 (WNT974) in combination with the experimental immunotherapy PDR001 (spartalizumab).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer with no other treatment options available.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LGK974 (WNT974), by mouth</li> <li class="seamTextUnorderedListItem">PDR001 (spartalizumab), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Wnt pathway is a network of proteins that may play a role in how cancer develops. </li> <li class="seamTextUnorderedListItem">LGK974 (WNT974) is a targeted therapy designed to inhibit the Wnt pathway.</li> <li class="seamTextUnorderedListItem">PDR001 (spartalizumab) is a type of immunotherapy called a PD-1 inhibitor. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced or metastatic cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01351103' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/publications/cancer-frontline/phase-i-clinical-trial-shows-wnt974-in-combination-with-spartalizumab-well-tolerated-for-advanced-solid-tumor-patients.h00-159381156.html' target='_blank'>MD Anderson Cancer Center: Phase I clinical trial shows WNT974 in combination with spartalizumab well tolerated for advanced solid tumor patients</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/porcupine-inhibitor-wnt974' target='_blank'>NCI Drug Dictionary: LGK974 (WNT974)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/spartalizumab' target='_blank'>NCI Drug Dictionary: PDR001 (Spartalizumab)</a> </li></ul>
34
NEAREST SITE: 339 miles
Novartis Investigative Site
Santa Monica,CA
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT02890069
Immunotherapy Plus a Targeted Drug for Advanced Triple Negative Breast Cancer
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589) Scientific Title
Purpose
To look at whether a new checkpoint inhibitor, a type of immunotherapy drug, is safe and effective when given along with a targeted drug.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer. (ER-, PR, HER2-) Your cancer must have progressed on or not responded to available therapies.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PDR001 and LCL161</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PDR001 and everolimus (Afinitor®)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PDR001 and Panobinostat (LBH589)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The immunotherapy drug used in this study is called PDR001. </li> <li class="seamTextUnorderedListItem">You will receive one of three targeted drugs: LCL161, everolimus (Afinitor®), or panobinostat (LBH589).</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02890069' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2016-01890' target='_blank'>Cancer.gov Trial Information</a> </li></ul>
35
NEAREST SITE: 339 miles
The Angeles Clinic and Research Institute
Los Angeles,CA
VISITS: May require hospitalization
PHASE: I
NCT ID: NCT04025216
CAR-T Immunotherapy for Metastatic Triple Negative & ER-Low Breast Cancer That is TnMUC1-Positive
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma Scientific Title
Purpose
To study the safety, best dose, side effects (good and bad), and anti-cancer activity of a new CAR-T cell immunotherapy that targets cancer cells that test positive for MUC1.
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer that tests positive for the antigen TnMUC1. You must have already tried at least one other treatment regimen that included a PD-L1 or PD-1 inhibitor if your tumor is PD-L1 positive.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®) and fludarabine (Fludara®), by IV, once, before the CART-T immunotherapy is given</li> <li class="seamTextUnorderedListItem">CART-TnMUC1, by IV, once</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule. May require hospital stay.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">CAR-T is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">The cells are removed from your blood, modified with chimeric antigen receptors (CARs) that allow them to attack proteins on cancer cells, and then put back in your body. </li> <li class="seamTextUnorderedListItem">The CAR-T therapy being used in this study trains the immune system to attack MUC1-positive cancer cells. </li> <li class="seamTextUnorderedListItem">Before you have the CAR-T cell therapy, you will be given the chemotherapy drugs fludarabine and cyclophosphamide. These drugs are given to prepare your immune system to receive the CAR-T cells. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancers that test TnMUC1-positive.</li> <li class="seamTextUnorderedListItem">Targets or mutations: TnMUC1</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04025216' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy' target='_blank'>NCI Dictionary of Cancer Terms: CAR T-cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/faq-about-car-t-cell-therapy/' target='_blank'>Dana-Farber Cancer Institute: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tmunity.com/pipeline' target='_blank'>Drug Company Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/MUC1' target='_blank'>Wikipedia: MUC1</a> </li></ul>
36
NEAREST SITE: 339 miles
UCLA Health
Santa Monica,CA
VISITS: 1 visit every 3 weeks, ongoing
PHASE: I
NCT ID: NCT03650348
PRS-343 With Tecentriq in HER2 Positive Advanced Breast Cancer
A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors Scientific Title
Purpose
To determine the best dose, safety and effects (good and bad) of PRS-343 when it is given along with atezolizumab (Tecentriq®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive breast cancer and have been treated with at least one systemic therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRS-343, by IV, once every 3 weeks</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, once every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRS-343 is a new type of HER2-targeted therapy. </li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor. It is approved to treat advanced <span class="highlight">triple</span>-<span class="highlight">negative</span> breast cancer, when used along with paclitaxel, in patients whose tumor tests positive for PD-L1.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03650348' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2019/atezolizumab-triple-negative-breast-cancer-fda-approval' target='_blank'>Cancer.gov: Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/791831' target='_blank'>NCI Drug Dictionary: Anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343</a> </li></ul>
37
NEAREST SITE: 341 miles
Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute
Los Angeles,CA
VISITS: Visits every 3 weeks, ongoing
PHASE: I-II
NCT ID: NCT03310957
SGN-LIV1A and Keytruda for Advanced Triple Negative Breast Cancer
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer Scientific Title
Purpose
To look at the safety and effects (good and bad) of using SGN-LIV1A along with pembrolizumab (Keytruda®) to treat triple negative advanced or metastatic breast cancer.
Who is this for?
People with advanced (some stage III) and metastatic (stage IV) breast cancer that is triple negative. You may not have received prior treatment for metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-LIV1A, by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-LIV1A is an investigational drug that targets a protein called LIV-1 that is found on some tumor cells. </li> <li class="seamTextUnorderedListItem">Keytruda® is a type of immunotherapy drug called a PD-1 inhibitor. It blocks the PD-1 (programmed cell death-1) protein, making it possible for the body's immune system to go after cancer cells. </li> <li class="seamTextUnorderedListItem">Keytruda® is approved to treat certain types of cancer, including breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03310957' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ascopost.com/News/20659' target='_blank'>ASCO Post: Keytruda for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2305936' target='_blank'>Seattle Genetics: SGN-LIV1A</a> </li></ul>
38
NEAREST SITE: 348 miles
Research Site
Los Angeles,CA
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT02264678
Ceralasertib Alone or With Chemotherapy or With Olaparib in Advanced Breast Cancer
A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies. Scientific Title
Purpose
To study the safety, effects, and best dose of Ceralasertib when it is used alone or with the chemotherapy drug carboplatin or the PARP inhibitor olaparib (Lynparza®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Open to all MBC patients</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ceralasertib, by mouth </li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks for up to 4.5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Open to all MBC patients </i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ceralasertib, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Open to <span class="highlight">Triple</span> <span class="highlight">Negative</span> Breast Cancer MBC patients with or without a BRCA mutation</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ceralasertib, by mouth</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 biopsies</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ceralasertib is a new type of targeted therapy called an ATR inhibitor. </li> <li class="seamTextUnorderedListItem">It disrupts a cancer cell's ability to repair its own DNA, which can cause the cancer cells to die. </li> <li class="seamTextUnorderedListItem">Carboplatin is a chemotherapy drug used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">Lynparza is a PARP inhibitor approved to treat BRCA 1 or BRCA 2 positive metastatic breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02264678' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atr-kinase-inhibitor-azd6738' target='_blank'>NCI Drug Dictionary: Ceralasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/olaparib' target='_blank'>NCI Drug Dictionary: Olaparib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/publications/oncology-live/2018/vol-19-no-24/targeting-cancers-achilles-heel-dna-damage-response-networks-beyond-parp' target='_blank'>OncLive: DNA Damage Response Networks Beyond PARP</a> </li></ul>
39
NEAREST SITE: 353 miles
City Of Hope National Medical Center
Duarte,CA
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT02419417
BMS-986158 for Advanced Triple Negative Breast (and Other) Cancer
A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors Scientific Title
Purpose
To investigate whether a new targeted drug for triple negative breast cancer is safe and effective.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following at increasing does until the maximum tolerated dose is reached: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BMS-986158, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The new drug being studied is called BMS-986158. It is currently only available in clinical trials. </li> <li class="seamTextUnorderedListItem">This study also is enrolling patients with other types of advanced cancers.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02419417' target='_blank'>ClinicalTrials.gov</a> </li></ul>
40
NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte,CA
VISITS: 2-3 visits every month, ongoing
PHASE: I-II
NCT ID: NCT03853707
Ipatasertib, Carboplatin and Paclitaxel in Metastatic Triple Negative & ER-Low Breast Cancer
A Phase I/IB Study of Ipatasertib in Combination With Carboplatin or Carboplatin/Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer Scientific Title
Purpose
To determine the best dose of ipatasertib (GDC-0068) when it is used along with paraplatin (Carboplatin®) alone or with paraplatin (Carboplatin®) and paclitaxel (Taxol®).
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer that has not responded to standard treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: With Paclitaxel</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, once daily, ongoing</li> <li class="seamTextUnorderedListItem">Paraplatin (Carboplatin®), by IV, 2 or 3 times a month, ongoing</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, 2 or 3 times a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Without Paclitaxel</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, once daily, ongoing</li> <li class="seamTextUnorderedListItem">Paraplatin (Carboplatin®), by IV, 2 or 3 times a month, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Ipatasertib is an investigational targeted therapy that blocks a protein called AKT that helps cancer cells grow and divide. </li> <li class="seamTextUnorderedListItem">Carboplatin and Taxol are chemotherapy drugs used to treat breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03853707' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ascopost.com/News/57955' target='_blank'>ASCO Post: AKT Inhibitor Ipatasertib in Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/conference-coverage/asco-2018/data-support-phase-3-trial-with-akt-inhibitor-in-triple-negative-breast-cancer' target='_blank'>OncLive: Early OS Data Support Phase III Trial With AKT Inhibitor Ipatasertib for TNBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdz133/5485241' target='_blank'>Annals of Oncology: Targeting the PI3-kinase pathway in triple-negative breast cancer</a> </li></ul>
41
NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte,CA
VISITS: 2 visits every 3 weeks, ongoing
PHASE: I
NCT ID: NCT02996825
Mirvetuximab Soravtansine & Chemotherapy in FRa+ Metastatic Triple Negative Breast Cancer
A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC) Scientific Title
Purpose
To test the safety and effects (good and bad) of a new drug called mirvetuximab soravtansine when it is given with the chemotherapy drug gemcitabine (Gemzar®).
Who is this for?
People with stage IV metastatic breast cancer that is triple negative (ER-, PR- and HER2-) and folate receptor (FR) alpha-positive. You must not have had more than four lines of chemotherapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mirvetuximab soravtansine, by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Gemcitabine/Gemzar®, by IV, twice every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mirvetuximab soravtansine is an antibody drug conjugate (ADC). </li> <li class="seamTextUnorderedListItem">It uses a drug that targets folate receptors on cancer cells to deliver the chemotherapy drug soravtansine directly to the tumor. </li> <li class="seamTextUnorderedListItem">Gemzar® is a chemotherapy drug approved to treat metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">This study also is enrolling patients with other types of FR+ tumors.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02996825' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mirvetuximab-soravtansine' target='_blank'>NCI Dictionary: Mirvetuximab Soravtansine</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gemcitabine-hydrochloride' target='_blank'>NCI Dictionary: Gemcitabine Hydrochloride</a> </li></ul>
42
NEAREST SITE: 359 miles
Research Site
Whittier,CA
VISITS: 3 visits a month for at least 6 months
PHASE: III
NCT ID: NCT03997123
Capivasertib & Paclitaxel as First Line Treatment for Advanced Triple Negative Tumors
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC. (CapItello290) Scientific Title
Purpose
To compare the effects (good and bad) and effectiveness of paclitaxel (Taxol®) and capivasertib to paclitaxel (Taxol®) and a placebo.
Who is this for?
People who are receiving their first treatment for advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capivasertib, by mouth, 4 times a week, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, once a week, 3 weeks on, 1 week off, for at least 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by mouth, 4 times a week, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, once a week, 3 weeks on, 1 week off, for at least 6 months</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug that is used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">Capivasertib is a targeted therapy drug that blocks Akt.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03997123' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/akt-inhibitor-azd5363' target='_blank'>NCI Drug Dictionary: Capivasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/conference-coverage/asco-2019/capivasertib-combined-with-fulvestrant-improves-pfs-in-er-breast-cancer' target='_blank'>Oncolive: Capivasertib Combined With Fulvestrant Improves PFS in ER+ Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.medpagetoday.com/meetingcoverage/asco/80249' target='_blank'>Medpage Today: AKT Inhibitor Doubles PFS in Advanced Breast Cancer</a> </li></ul>
43
NEAREST SITE: 363 miles
Pacific Shores Medical Group
Long Beach,CA
VISITS: 1 visit weekly
PHASE: I
NCT ID: NCT03800836
Ipatasertib with Atezolizumab & Paclitaxel or Nab-Paclitaxel in Advanced TNBC
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer Scientific Title
Purpose
To evaluate the safety and effects (good and bad) of using ipatasertib in combination with atezolizumab (Tecentriq®) and either paclitaxel (Taxol®) or nab-paclitaxel (Abraxane®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: with Paclitaxel</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, daily, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, once every 2 weeks </li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, 3 weeks on, 1 week off</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: with Nab-Paclitaxel</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, daily, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, once every 2 weeks </li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®), by IV, weekly, 3 weeks on, 1 week off</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ipatasertib is an investigational targeted therapy that blocks a protein called AKT that helps cancer cells divide and grow. </li> <li class="seamTextUnorderedListItem">Tecentriq is an immunotherapy that is approved for use in combination with Taxol to treat PD-L1-positive advanced <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer. </li> <li class="seamTextUnorderedListItem">Taxol and Abraxane are chemotherapy drugs used to treat breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03800836' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/04/01/mbc-news-10/' target='_blank'>MetastaticTrialTalk: Tecentriq® (Atezolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.biooncology.com/pipeline-molecules/ipatasertib.html' target='_blank'>Drug information page: Ipatasertib</a> </li></ul>
44
NEAREST SITE: 366 miles
University of California, Los Angeles
Santa Monica,CA
VISITS: At least 1 visit per month
PHASE: II
NCT ID: NCT03207867
Combination Immunotherapies for Advanced Triple Negative Breast Cancer
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma Scientific Title
Purpose
To study the safety and effects (good and bad) of using two different types of immunotherapy drugs at the same time to treat advanced triple negative breast cancer.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NIR178, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">PDR001, by IV, monthly, ongoing</li> <li class="seamTextUnorderedListItem">2 biopsies</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The two experimental immunotherapies being used in this study are NIR178 and PRD001.</li> <li class="seamTextUnorderedListItem">NIR178 is an adenosine receptor antagonist. It blocks adenosine, which is found in the microenvironment that surrounds the tumor. </li> <li class="seamTextUnorderedListItem">PDR001 is a type of immunotherapy called a PD-1 inhibitor. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling patients with other types of advanced cancers.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03207867' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/navigating-cancer-care/how-cancer-treated/immunotherapy-and-vaccines/understanding-immunotherapy' target='_blank'>Cancer.net: Understanding Immunotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://immuno-oncologynews.com/pdr001/' target='_blank'>Immuno-Oncology News: PDR001</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.novartis.com/news/media-releases/novartis-continues-grow-immuno-oncology-pipeline-through-collaboration-and' target='_blank'>Novartis: NIR178</a> </li></ul>
45
NEAREST SITE: 426 miles
Research Site
Palm Springs,CA
VISITS: 5 initial visits, then 1 visit every 2 months for 18 months, then 1 visit every 3 months
PHASE: II
NCT ID: NCT03330847
Lynparza Alone or with Ceralasertib in Metastatic Triple Negative Breast Cancer
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant... (VIOLETTE) Scientific Title
Purpose
To compare the safety and effects (good and bad) of using olaparib (Lynparza®) alone to using olaparib (Lynparza®) in combination with the experimental targeted therapy ceralasertib (AZD6738).
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have received at least one but no more than two lines of chemotherapy for metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily</li> <li class="seamTextUnorderedListItem">Ceralasertib (AZD6738), by mouth, once a day (1 week on, 3 weeks off)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">While your tumor will be tested for mutations in genes that are part of the homologous recombination repair (HRR) pathway, which includes BRCA 1/2, a mutation in the HRR pathway is not required for enrollment. </li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of drug called a PARP inhibitor. PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA. It is approved for use in metastatic inherited BRCA1/2 mutation, HER2 negative breast cancer. </li> <li class="seamTextUnorderedListItem">Ceralasertib (AZD6738) is an experimental targeted therapy drug that targets DNA damage repair.</li> <li class="seamTextUnorderedListItem">Targets or mutations: HRR (homologous recombination repair) pathway, BRCA 1, BRCA 2</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03330847' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm592357.htm' target='_blank'>FDA approves olaparib for germline BRCA-mutated metastatic breast cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lynparza.com/' target='_blank'>AstraZeneca Drug Information Page: Lynparza</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atr-kinase-inhibitor-azd6738' target='_blank'>NCI Drug Dictionary: Ceralasertib</a> </li></ul>
46
NEAREST SITE: 441 miles
UC San Diego Moores Cancer Center
San Diego,CA
VISITS: 1 visit every 2 weeks, for 2 months
PHASE: I
NCT ID: NCT03752398
XmAb23104 for Advanced Triple Negative Breast Cancer (DUET-3)
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors Scientific Title
Purpose
To study the safety, effects (good and bad) and the best dose of an experimental immunotherapy called XmAb23104.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR-, HER2-) that has not responded to other treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XmAb23104, by IV, every 2 weeks, for 2 months</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">XmAb23104 targets both PD-1 (programmed cell death protein 1) and ICOS (inducible T-cell co-stimulator). </li> <li class="seamTextUnorderedListItem">This study is enrolling people with other types of metastatic cancers.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03752398' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/796973' target='_blank'>NCI drug dictionary: XmAb23104</a> </li></ul>
47
NEAREST SITE: 441 miles
University of California San Diego Medical Center; Moores Cancer Center
La Jolla,CA
VISITS: At least 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT03424005
Tecentriq & Targeted Therapy or Chemotherapy for Metastatic Triple Negative Breast Cancer
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC) Scientific Title
Purpose
To study the safety and effects (good and bad) of 7 different immunotherapy-based treatment combinations in people with triple negative (ER-/PR-/HER2-) breast cancer.
Who is this for?
People with triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer that progressed during or following first-line metastatic treatment with chemotherapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 7 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth (2 weeks on, 1 week off), ongoing </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, daily (3 weeks on, 1 week off), ongoing </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">SGN-LIV1A, by IV, every 3 weeks, ongoing </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®), by IV, once or twice every 3 weeks, ongoing </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 5</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®), by IV, once or twice every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Cobimetinib (Cotellic®), by mouth, daily (3 weeks on, 1 week off), ongoing </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 6</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®), by mouth, daily (2 weeks on, 1 week off), ongoing </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 7</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Physician's choice chemotherapy (gemcitabine/Gemzar® plus carboplatin/Paraplatin®, or eribulin/Halaven®), by IV, weekly (2 weeks on, 1 week off), ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The immunotherapy being used in this study is atezolizumab (Tecentriq®). It is a PD-L1 inhibitor that works by stimulating the body's immune system to go after cancer cells.</li> <li class="seamTextUnorderedListItem">Tecentriq is approved to treat certain types of urinary, bladder and lung cancer.</li> <li class="seamTextUnorderedListItem">The targeted therapies being used in the study are Ipatasertib (GDC-0068), SGN-LIV1A, bevacizumab (Avastin®) and cobimetinib (Cotellic®).</li> <li class="seamTextUnorderedListItem">The chemotherapies being used in this study are capecitabine (Xeloda®), gemcitabine (Gemzar®), carboplatin (Paraplatin®) and eribulin (Halaven®).</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03424005' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/EmergingMetasticBreastCancer.html' target='_blank'>Komen: Emerging Areas in Metastatic Breast Cancer Treatment</a> </li></ul>
48
NEAREST SITE: 441 miles
University of California, San Diego
La Jolla,CA
VISITS: Visits weekly over 6 months
PHASE: I
NCT ID: NCT02776917
A New Targeted Therapy and Taxol for Advanced Breast Cancer
A Phase 1b Pilot Clinical Trial of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic, or Locally Advanced, Unresectable Breast Cancer Scientific Title
Purpose
To investigate the safety and effects (good and bad) of a new type of targeted therapy when it is given along with the chemotherapy drug paclitaxel (Taxol®) to treat advanced breast cancer.
Who is this for?
People with triple negative (ER-, PR-, or HER2-) or hormone receptor positive (ER+ or PR+), advanced (some stage III) or metastatic (stage IV) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cirmtuzumab, by IV, weekly (2 weeks on, 2 weeks off), over 6 months</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, ongoing</li> <li class="seamTextUnorderedListItem">Blood and tissue sample collection</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The experimental targeted therapy is cirmtuzumab. It targets ROR1, a protein found only on cancer cells. </li> <li class="seamTextUnorderedListItem">Taxol is commonly used to treat breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02776917' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://health.ucsd.edu/news/releases/Pages/2018-08-27-researchers-to-test-novel-drug-combination-against-toughest-breast-cancer.aspx' target='_blank'>UCSD Health Article</a> </li></ul>
49
NEAREST SITE: 441 miles
University of CA San Diego
La Jolla,CA
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT03435640
NKTR-262 and NKTR-214 with or without Opdivo for Advanced TNBC (and Other) Cancers
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies (REVEAL) Scientific Title
Purpose
To evaluate the safety and best dose of two experimental immunotherapy drugs when they are given with or without the immunotherapy drug nivolumab (Opdivo®) to treat advanced breast cancer.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that is triple negative breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NKTR-262, by injection, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">NKTR-214, by IV, every 3 weeks, ongoing </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NKTR-262, by injection, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">NKTR-214, by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, every 3 weeks, ongoing</li></ul>
-
<p class="seamTextPara"> INKTR-262 and NKTR-214 are the experimental immunotherapy drugs being used in this study. </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Opdivo is a type of immunotherapy drug called a PD-1 inhibitor. It is approved to treat certain types of metastatic melanoma and non-small cell lung cancer.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03435640' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.onclive.com/web-exclusives/nktr-214-nivolumab-combination-shows-promise-in-early-study' target='_blank'>OncLive: NKTR-214 and Nivolumab</a> </li></ul>
50
NEAREST SITE: 533 miles
OHSU Knight Cancer Institute
Portland,OR
VISITS: Monthly visits for 1 year
PHASE: II
NCT ID: NCT03801369
Olaparib and Durvalumab in Metastatic Triple Negative & ER-Low Breast Cancer
A Phase II, Open Label, Study of Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Triple Negative Breast Cancer Scientific Title
Purpose
To evaluate the safety and effects (good and bad) of using the combination of olaparib (Lynparza®) and durvalumab (Imfinzi®).
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily for 1 month, then once a month for 1 year</li> <li class="seamTextUnorderedListItem">Durvalumab (Imfinzi®), by IV, monthly, for 1 year</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">2-3 tumor biopsies</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Lynparza is a PARP inhibitor. It stops the growth of cancer cells by blocking enzymes called poly ADP ribose polymerase (PARP). </li> <li class="seamTextUnorderedListItem">It is approved to treat certain types of ovarian cancer. </li> <li class="seamTextUnorderedListItem">Imfinzi is a type of immunotherapy drug called a PD-L1 inhibitor. It gets the body's immune system to go after cancer cells. </li> <li class="seamTextUnorderedListItem">It is approved to treat certain types of lung cancer. </li> <li class="seamTextUnorderedListItem">Preclinical studies suggest this drug combination may be effective in patients with metastatic <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03801369' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.imfinzi.com/stage-3-nsclc/about/how-imfinzi-works.html?source=imz_c_c_45&umedium=cpc&uadpub=google&ucampaign=2018imfinzidtcnsclcbranded_general&ucreative=branded_alone_ex&uplace=durvalumab&outcome=dtc&cmpid=1' target='_blank'>Durvalumab (Imfinzi®) Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lynparza.com/ovarian-cancer/recurrent-ovarian-cancer.html?source=lyn_d_c_2&umedium=cpc&uadpub=google&ucampaign=lynparzadtcbranded_alone_2019&ucreative=branded_alone_ex&uplace=olapariblynparza&outcome=dtc&cmpid=1' target='_blank'>Olaparib (Lynparza®) Drug Information Page</a> </li></ul>
51
NEAREST SITE: 602 miles
Novartis Investigative Site
Salt Lake City,UT
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT02947165
NIS793 with Spartalizumab (PDR001) in Patients With Advanced Triple Negative Breast Cancer
A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies Scientific Title
Purpose
To study the safety, effects (good and bad) and best dose of NIS793 when it is used alone or with an immunotherapy.
Who is this for?
People with locally advanced (stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) and have no other standard treatment options available.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NIS793, by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Spartalizumab (PDR001), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">NIS793, by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NIS793 is a targeted therapy that binds to the transforming growth factor-beta receptor. </li> <li class="seamTextUnorderedListItem">Spartalizumab is the investigational immunotherapy being used in this study. It is a type of immunotherapy called a PD-L1 checkpoint inhibitor. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of solid tumors.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02947165' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/spartalizumab' target='_blank'>NCI Dictionary: Spartalizumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-tgf-beta-monoclonal-antibody-nis793' target='_blank'>NCI Dictionary: NIS793</a> </li></ul>
52
NEAREST SITE: 637 miles
Research Site
Goodyear,AZ
VISITS: Approximately 1 visit a week
PHASE: I-II
NCT ID: NCT03742102
Imfinzi & Taxol with Capivasertib, Danvatirsen or Oleclumab for First Line Metastatic TNBC
A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination With Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer. (BEGONIA) Scientific Title
Purpose
To look at the safety and effects (good and bad) of the combination of durvalumab (Imfinzi®) and paclitaxel (Taxol®) when used alone or with one of three additional therapies.
Who is this for?
Women with metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) being treated for the first time for metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Durvalumab (Imfinzi®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, 3 weeks on and 1 week off</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Durvalumab (Imfinzi®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, 3 weeks on and 1 week off</li> <li class="seamTextUnorderedListItem">Capivasertib (AZD5363), by mouth, twice a day, 3 weeks on and 1 week off</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Durvalumab (Imfinzi®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, 3 weeks on and 1 week off</li> <li class="seamTextUnorderedListItem">Danvatirsen (AZD9150), by IV, 3 times in the first week and then weekly</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Durvalumab (Imfinzi®), by IV, monthly</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, 3 weeks on and 1 week off</li> <li class="seamTextUnorderedListItem">Oleclumab (MEDI9447), by IV, once every 2 weeks for 1 month, then monthly</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imfinzi is a type of immunotherapy called a PD-L1 (programmed cell death ligand-1) inhibitor. It has been approved to treat certain types of cancers, and its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Taxol is a chemotherapy drug routinely used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">The three additional therapies are capivasertib, a targeted therapy that blocks Akt; danvatirsen, a targeted therapy that blocks the STAT3 protein; and oleclumab, which targets CD73.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03742102' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/conference-coverage/asco-2019/capivasertib-combined-with-fulvestrant-improves-pfs-in-er-breast-cancer' target='_blank'>OncLive: Capivasertib Combined With Fulvestrant Improves PFS in ER+ Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/stat3-antisense-oligonucleotide-isis-481464' target='_blank'>NCI Drug Dictionary: Danvatirsen</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd73-monoclonal-antibody-medi9447' target='_blank'>NCI Drug Dictionary: Oleclumab</a> </li></ul>
53
NEAREST SITE: 650 miles
Mayo Clinic
Phoenix,AZ
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT04301011
Immunotherapy TBio-6517 Alone or With Pembrolizumab for Advanced Triple Negative Breast Cancer
A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered by Intratumoral Injection, Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors (RAPTOR) Scientific Title
Purpose
To determine the best dose and to study the effects (good and bad) of using the immunotherapy TBio-6517 alone and in combination with the immunotherapy pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer. If your tumor is PD-L1 positive, you must have already received a PD-L1 or a PD-1 targeted therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will participate in either Phase 1 or Phase 2: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Phase 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TBio-6517, by injection directly into your tumor, 4 times (you may also receive boosters for up to 2 years)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Phase 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TBio-6517, by injection directly into your tumor, 4 times (you may also receive boosters for up to 2 years)</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TBio-6517 is an immunotherapy that is injected directly into your tumor.</li> <li class="seamTextUnorderedListItem">TBio-6517 is an experimental drug, this means it is only available in clinical trials.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a checkpoint inhibitor. It gets the immune system to go after cancer cells by blocking PD-1. It is approved for use in some cancers but its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04301011' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://turnstonebio.com/#about-us' target='_blank'>Turnstone Biologics Drug Information Page: TBio-6517 (RIVAL-01)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com' target='_blank'>Merck Oncology Drug Information Page: Keytruda® (Pembrolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/keytruda-plus-chemo-better-than-chemo-alone-for-some' target='_blank'>Breastcancer.org: Keytruda Plus Chemotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
54
NEAREST SITE: 671 miles
Banner MD Anderson Cancer Center
Gilbert,AZ
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT03901469
ZEN003694 and Talazoparib for Triple Negative & ER-Low Breast Cancer
A Phase 2 Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast Cancer Scientific Title
Purpose
To look at the safety and effects (good and bad) of using the experimental drug ZEN003694 along with talazoparib (Talzenna®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer who have been tested for and found to not have inherited a BRCA1 or BRCA2 mutation
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZEN003694, by mouth, once daily </li> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, once daily</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">ZEN003694 is a drug taken by mouth that targets the protein BET. </li> <li class="seamTextUnorderedListItem">This protein helps cancer cells grow. </li> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®) is a PARP inhibitor. </li> <li class="seamTextUnorderedListItem">It prevents the PARP protein from repairing damaged DNA inside tumor cells. </li> <li class="seamTextUnorderedListItem">It is approved to treat HER2-negative locally advanced or metastatic breast cancer in people with an inherited BRCA mutation.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03901469' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/web-exclusives/fda-approves-talazoparib-for-brcamutated-her2negative-breast-cancer' target='_blank'>OncLive: FDA Approves Talazoparib for BRCA-Mutated, HER2-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bet-bromodomain-inhibitor-zen-3694' target='_blank'>NCI Drug Dictionary: BET bromodomain inhibitor ZEN-3694</a> </li></ul>
55
NEAREST SITE: 671 miles
Banner MD Anderson Cancer Center
Gilbert,AZ
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT04115306
Targeted Therapy PMD-026 for Metastatic Triple Negative Breast Cancer
Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients With Metastatic Breast Cancer With Expansion in Metastatic Triple Negative Breast Cancer Scientific Title
Purpose
To determine the best dose, safety, and effects of the drug PMD-026.
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer with no standard treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PMD-026, by mouth, daily, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PMD-026 is an experimental therapy that targets RSK2, a protein that plays a role in cancer cell growth.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04115306' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://phoenixmd.ca/pipeline' target='_blank'>Drug Company Information Page: PMD-026</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/29498411' target='_blank'>PubMed Abstract: RSK1 Promotes Murine Breast Cancer Growth and Metastasis</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Ribosomal_s6_kinase' target='_blank'>Wikipedia: RSK</a> </li></ul>
56
NEAREST SITE: 682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle,WA
VISITS: 2-3 visits over 1-2 months; may include hospital stay
PHASE: I
NCT ID: NCT02706392
CAR T-Cell Therapy For Metastatic Triple Negative & ER-Low Breast Cancer that is ROR1 Positive
Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor Scientific Title
Purpose
To assess the safety, effects (good and bad) and best dose of an experimental CAR-T immunotherapy that targets cancer cells that test positive for ROR1.
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer that has not responded to other treatment options and that tests positive for ROR1.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leukapheresis (blood draw for the collection of cells) </li> <li class="seamTextUnorderedListItem">Chemotherapy (cyclophosphamide and fludarabine), 1 or 2 times over 3 weeks</li> <li class="seamTextUnorderedListItem">ROR1 CAR-T cells, by IV, 1 or 2 times over 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Hospital stay may be required</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">CAR-T is a personalized immunotherapy made from a patient's white blood cells. </li> <li class="seamTextUnorderedListItem">The blood cells are removed from the patient and then modified with chimeric antigen receptors (CARs) so they can attack specific proteins. The cells are then infused back into the patient in the hospital. </li> <li class="seamTextUnorderedListItem">The CAR-T therapy being used in this study trains the immune system to attack ROR1-positive tumor cells. </li> <li class="seamTextUnorderedListItem">It is given along with the chemotherapy drugs fludarabine phosphate and cyclophosphamide. These drugs are given to deplete lymph cells. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of ROR1-positive metastatic tumors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ROR1</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02706392' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertherapyadvisor.com/sabcs-2018/cart-trial-triple-negative-breast-cancer-start-tnbc/article/819085/' target='_blank'>Cancer Therapy Advisor: CAR-T Trial for Triple-Negative Breast Cancer Under Way</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.drsusanloveresearch.org/videos/chimeric-antigen-receptor-t-cell-car-t-therapy' target='_blank'>Dr. Susan Love Research Foundation: Chimeric Antigen Receptor T-Cell (CAR-T) Therap</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/26874851' target='_blank'>Pubmed: Expression of ROR1 has prognostic significance in triple negative breast cancer.</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_1227' target='_blank'>SABCS 2018 Abstract: Trial update (ROR1-CAR)</a> </li></ul>
57
NEAREST SITE: 682 miles
University of Washington Seattle Cancer Center
Seattle,WA
VISITS: At least 1 visit every 2 months
PHASE: I-II
NCT ID: NCT03997968
CYT-0851 for Advanced Solid Tumors and Some Types of Blood Cancers
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors Scientific Title
Purpose
To study the safety and best dose of CYT-0851, a type of targeted therapy called a RAD51 inhibitor.
Who is this for?
People with triple negative (ER-, PR-, HER2-) metastatic (stage IV) breast cancer that tests positive for a protein called activation-induced cytidine deaminase (AID).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CYT-0851, by mouth, ongoing</li> <li class="seamTextUnorderedListItem">1 biopsy</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RAD51 is a protein that helps cells repair DNA damage. Blocking this process may keep tumors from growing. </li> <li class="seamTextUnorderedListItem">Tumors that test positive for a protein called activation-induced cytidine deaminase (AID) may have high rates of DNA damage. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling patients with other types of cancers.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03997968' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/breast-cancer/rad51-linked-parp-inhibitor-resistance-brca-mutated-breast-cancer' target='_blank'>CancerNetwork.com: RAD51</a> </li></ul>
58
NEAREST SITE: 941 miles
University of Colorado Cancer Center
Aurora,CO
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT02719691
MLN0128 and Alisertib for Metastatic Triple-Negative Breast (and Other Advanced) Cancers
A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC) Scientific Title
Purpose
To determine if the combination of Alisertib and MLN0128, an mTOR inhibitor, is safe and effective.
Who is this for?
People with metastatic (stage IV) triple negative breast cancer. You must have received one prior round of chemotherapy, either following surgery for early breast cancer or for metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alisertib (MLN8237), by mouth, twice daily, for 1 week every month</li> <li class="seamTextUnorderedListItem">MLN0128, by mouth daily, for 2-3 weeks every month</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MLN0128 is a new type of targeted therapy called an mTOR inhibitor.</li> <li class="seamTextUnorderedListItem">Alisertib (MLN8237) is a new targeted therapy that blocks an enzyme--Aurora A kinase--that helps cancer cells grow.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02719691' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/ct2/show/study/NCT02719691#contacts' target='_blank'>ClinicalTrials.gov: Trial Information</a> </li></ul>
59
NEAREST SITE: 941 miles
University of Colorado Denver
Aurora,CO
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03739931
mRNA-2752 & Durvalumab for Advanced Triple Negative Breast Cancer
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade Scientific Title
Purpose
To study the safety, best dose and effects (good and bad) of mRNA-2752 when it is combined with durvalumab (Imfinzi®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer that has already been treated with adequate standard of care therapies.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem"> mRNA-2752, by injection</li> <li class="seamTextUnorderedListItem">IMFINZI® (durvalumab), by IV</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">mRNA-2752 is injected directly into a tumor. It is designed to make a tumor more responsive to an immunotherapy drug. </li> <li class="seamTextUnorderedListItem">Imfinzi® is a type of immunotherapy called a PD-L1 (programmed cell death ligand-1) inhibitor. It works by stimulating the body's immune system to go after cancer cells. It has been approved to treat certain types of cancers. Its use in breast cancer is considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03739931' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.imfinzi.com/stage-3-nsclc/about/how-imfinzi-works.html?source=imz_c_c_45&umedium=cpc&uadpub=google&ucampaign=2018imfinzidtcnsclcbranded_general&ucreative=branded_alone_ph&uplace=durvalumab&outcome=dtc&cmpid=1' target='_blank'>AstraZeneca Drug Information Page: Imfinzi®</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/796816' target='_blank'>NCI Drug Dictionary: mRNA-2752</a> </li><li class='seamTextUnorderedListItem'><a href='https://cancerres.aacrjournals.org/content/79/13_Supplement/CT210' target='_blank'>AACR Abstract: mRNA-2752</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.modernatx.com/pipeline/therapeutic-areas/immuno-oncology' target='_blank'>Drug Company Information Page: Intratumoral Immuno-Oncology Therapeutics</a> </li><li class='seamTextUnorderedListItem'><a href='https://stm.sciencemag.org/content/11/477/eaat9143.full?ijkey=nRihB/hFvaoUw&keytype=ref&siteid=scitransmed' target='_blank'>Journal Article: Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs</a> </li></ul>
60
NEAREST SITE: 948 miles
Sarah Cannon Research Institute at HealthOne
Denver,CO
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT04148937
The Targeted Therapy LY3475070 Alone or With Pembrolizumab in Advanced Breast Cancer
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies Scientific Title
Purpose
To study the safety, anti-cancer activity, and effects (good and bad) of the experimental targeted therapy LY3475070 when it is given alone or with the immunotherapy pembrolizumab (Keytruda®).
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) breast cancer who have no other standard treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3475070, by mouth, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3475070, by mouth, ongoing</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3475070 is a type of investigational therapy called a CD73 inhibitor. </li> <li class="seamTextUnorderedListItem">CD73 is a protein that may be a new biomarker in <span class="highlight">triple</span> <span class="highlight">negative</span> (ER-, PR-, HER2-) breast cancer. </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a checkpoint inhibitor. It gets the immune system to go after cancer cells by blocking PD-1.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is approved to treat certain other types of cancers. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This study also is enrolling patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04148937' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lillytrialguide.com/en-US/studies/advanced-cancer/jzma' target='_blank'>Eli Lilly & Company Trial Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytruda+Pan+Tumor_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=Brand+Keyword_General&kw=pembrolizumab&utm_kxconfid=sq7irm3mh&gclid=CjwKCAiA1L_xBRA2EiwAgcLKA1rjY2sDvGijJBKlq4pryVynCh4LO-tR1STTRbK7a6-qFcn3XQre2RoC' target='_blank'>Merck Oncology: Keytruda® (Pembrolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='http://tcr.amegroups.com/article/view/21463/html' target='_blank'>Journal Article: CD73, A New Biomarker in Triple-negative Breast Cancer</a> </li></ul>
61
NEAREST SITE: 1251 miles
Hays Medical Center Dreiling-Schmidt Cancer Institute
Hays,KS
VISITS: 1 visit
PHASE: NA
NCT ID: NCT02302742
A Registry for Patients with a Breast Cancer Genetic Mutation or Triple Negative Tumor
PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations (PROGECT) Scientific Title
Purpose
To learn more about the relationship between genetic mutations and cancer outcomes based on the cancer-related information collected.
Who is this for?
Women with triple negative breast cancer and/or inherited genetic mutations.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> This is a data collection (registry) study. Participants will undergo 1 blood test upon enrolling in this study.</p>
-
<p class="seamTextPara"> People who carry an inherited genetic mutation are at increased risk of developing breast cancer. </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BRCA1 and BRCA2 are the most common genetic mutations associated with breast cancer risk. But there are other mutations that also increase breast cancer risk, including PTEN, P53, PALB2, and others. </li> <li class="seamTextUnorderedListItem">Previous studies have found that individuals with <span class="highlight">triple</span>-<span class="highlight">negative</span> breast cancer are likely to carry the BRCA mutation.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02302742' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer' target='_blank'>Cancer.net: Hereditary Breast and Ovarian Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://ww5.komen.org/BreastCancer/InheritedGeneticMutations.html' target='_blank'>Susan G. Komen: Inherited Gene Mutations</a> </li></ul>
62
NEAREST SITE: 1387 miles
Stephenson Cancer Center
Oklahoma City,OK
VISITS: 1 visit every 3 weeks, ongoing
PHASE: I-II
NCT ID: NCT03775850
Immunotherapy EDP1503 With Pembrolizumab For Advanced Triple Negative Breast Cancer
A Phase I/II Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Scientific Title
Purpose
To assess the safety and the effects (good and bad) of the immunotherapy EDP1503 when it is given along with pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV),triple negative (ER-, PR-, HER2-) breast cancer who have no other approved treatment options available.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">EDP1503, by mouth, twice daily, for 2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">followed by</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">EDP1503, by mouth, twice daily </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">EDP1503 is an experimental immunotherapy that may work by changing the microenvironment that surrounds the cancer cells. </li> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy called a PD-1 inhibitor. </li> <li class="seamTextUnorderedListItem">It is only approved to treat certain types of breast cancers. Its use in this trial is considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03775850' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795263' target='_blank'>NCI: Monoclonal microbial EDP1503</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pharmacychoice.com/News/article.cfm?Article_ID=2142547' target='_blank'>Pharmacy Choice: Evelo Enters into Clinical Trial Collaboration Agreement with Merck</a> </li><li class='seamTextUnorderedListItem'><a href='https://globenewswire.com/news-release/2019/01/04/1680530/0/en/Evelo-Biosciences-Announces-Dosing-of-First-Patient-in-Phase-1-2-Clinical-Trial-of-EDP1503-in-Combination-with-KEYTRUDA-pembrolizumab-in-Multiple-Oncology-Indications.html' target='_blank'>Evelo Press Release: EDP1503</a> </li></ul>
63
NEAREST SITE: 1387 miles
University of Oklahoma
Oklahoma City,OK
VISITS: 2 visits per week, ongoing
PHASE: I
NCT ID: NCT03364400
VT1021 in Metastatic Triple Negative Breast Cancer
A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors Scientific Title
Purpose
To study the effects (good and bad) of the experimental drug VT1021.
Who is this for?
People with metastatic (stage IV), triple negative (ER-, PR-, HER2-) breast cancer who have already received at least three lines of therapy in the metastatic setting.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">VT1021, by IV, twice a week, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">VT1021 is an experimental targeted therapy that researchers believe may work by affecting the tumor's microenvironment (the tissue surrounding the tumor).</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03364400' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://vigeotherapeutics.com' target='_blank'>Drug Company Information Page: VT1021</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2020/03/03/mbc-news-20/' target='_blank'>Metastatic Trial Talk: The Tumor Microenvironment</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
64
NEAREST SITE: 1387 miles
Stephenson Cancer Center (Oklahoma University)
Oklahoma City,OK
VISITS: 1 visit a week, ongoing
PHASE: I-II
NCT ID: NCT04180371
BT5528 Alone or With Nivolumab in Advanced Triple Negative Breast Cancer That Tests EphA2+
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression Scientific Title
Purpose
To study the safety, effects (good and bad), and best dose of an experimental therapy called BT5528 when it is given alone or with nivolumab (Opdivo®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR-, HER2-), have already tried other cancer treatments, have no other standard treatment options, and have a tumor that tests positive for a protein called EphA2.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> This trial is being conducted in two parts. You will participate in 1 of 2 parts depending on when you enroll: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Part 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BT5528, by IV, once a week, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Part 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BT5528, by IV, once a week, ongoing</li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, once every 4 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BT5528 targets a protein called EphA2 that helps cancer cells grow. </li> <li class="seamTextUnorderedListItem">EphA2 is found on some <span class="highlight">triple</span> <span class="highlight">negative</span> breast tumors. </li> <li class="seamTextUnorderedListItem">Opdivo is a type of immunotherapy called a checkpoint inhibitor. It gets the immune system to go after cancer cells by blocking a protein called PD-1 (programmed cell death 1). It is approved to treat certain types of cancer. Its use in breast cancer is considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04180371' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bicycletherapeutics.com/programs/' target='_blank'>Bicycle Therapeutics Information Page: BT5528</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nature.com/articles/onc2017170' target='_blank'>Journal Article: Targeting EphA2 In Triple Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.opdivo.com/about-opdivo/how-opdivo-works-monotherapy' target='_blank'>Bristol-Meyers Squibb Information Page: Opdivo</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.curetoday.com/publications/cure/2019/immunotherapy-2019/breast-cancer-gets-a-boost-from-immunotherapy' target='_blank'>Cure Today: Breast Cancer Gets a Boost From Immunotherapy</a> </li></ul>
65
NEAREST SITE: 1387 miles
Research Site
Oklahoma City,OK
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03205176
AZD5153 Alone or With Olaparib in Advanced Triple Negative Breast Cancer
A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas Scientific Title
Purpose
To study the safety and effects (good and bad) of giving the targeted therapy AZD5153 alone and in combination with the PARP inhibitor olaparib (Lynparza®).
Who is this for?
People with advanced (stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have no standard treatment options available.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD5153, by mouth, daily, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD5153, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice a day, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD5153 is an investigational targeted therapy (only available in clinical trials). </li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of targeted therapy called a PARP inhibitor. It stops the growth of cancer cells by blocking enzymes called poly ADP ribose polymerase (PARP).</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is approved to treat metastatic, HER2 negative breast cancer in women with a hereditary BRCA 1 or BRCA 2 mutation. Its use in this trial is considered experimental. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03205176' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://openinnovation.astrazeneca.com/azd5153.html' target='_blank'>AstraZeneca Drug Information Page: AZD5153</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793144' target='_blank'>NCI Drug Dictionary: AZD5153</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lynparzahcp.com/ovarian-cancer/home.html?source=lyn_d_h_15&umedium=cpc&uadpub=google&ucampaign=lynparzahcpovarian_branded_alone_2019&ucreative=generic_alone_ex&uplace=olaparib&outcome=hcp&cmpid=1&gclid=CjwKCAjwpqv0BRABEiwA-TySwSHK0dvXHqFh8iMkn' target='_blank'>AstraZeneca Drug Information Page: Lynparza® (Olaparib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/lynparza' target='_blank'>Breastcancer.org: Lynparza® (Olaparib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
66
NEAREST SITE: 1387 miles
Stephenson Cancer Center
Oklahoma City,OK
VISITS: 1 to 4 visits monthly, ongoing
PHASE: I
NCT ID: NCT03829436
TPST-1120 Alone or With a Systemic Therapy in Advanced Triple Negative Breast Cancer
A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors Scientific Title
Purpose
To study the safety, best dose and effects (good and bad) of TPST-1120 when it is used alone or with another anti-cancer drug.
Who is this for?
People with triple negative advanced (some stage III) or metastatic (stage IV) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TPST-1120, by mouth, twice daily </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TPST-1120, by mouth, twice daily </li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, once a month</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TPST-1120, by mouth, twice daily </li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), by IV, once every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TPST-1120, by mouth, twice daily </li> <li class="seamTextUnorderedListItem">Cetuximab (Erbitux®), by IV, once a week</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TPST-1120 is an investigational drug that targets a protein called PPARα. </li> <li class="seamTextUnorderedListItem">The other drugs it may be given with are nivolumab (Opdivo®), docetaxel (Taxotere®), and cetuximab (Erbitux®). </li> <li class="seamTextUnorderedListItem">Opdivo is a type of immunotherapy called a PD-1 inhibitor. It has been approved to treat certain types of cancer. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Taxotere is a chemotherapy drug used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">Erbitux is a targeted therapy that blocks EGFR. It is approved to treat head, neck and colorectal cancer. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This trial also is enrolling patients with other types of advanced cancers.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03829436' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.medpagetoday.com/reading-room/asco/breast-cancer/79947' target='_blank'>Medpage Today: Cetuximab in Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.esmo.org/Oncology-News/Promising-Response-Rates-in-Patients-with-Metastatic-TNBC-Treated-with-Nivolumab-After-Induction-Treatment' target='_blank'>ESMO 2017: Promising Response Rates in Patients with Metastatic TNBC Treated with Nivolumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancercare.org.uk/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/docetaxel-taxotere' target='_blank'>Cancer Research UK: Docetaxel</a> </li><li class='seamTextUnorderedListItem'><a href='http://cancerres.aacrjournals.org/content/79/13_Supplement/3606' target='_blank'>Cancer Research: TPST-1120 suppresses tumor growth and stimulates anti-tumor immunity</a> </li></ul>
67
NEAREST SITE: 1479 miles
Mary Crowley Cancer Research Centers
Dallas,TX
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT03150810
BGB-290 with Temozolomide for Advanced Breast Cancer
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors Scientific Title
Purpose
To investigate the safety and effects (good and bad) of using an oral chemotherapy along with a new targeted drug to treat advanced breast cancer.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have not already received a PARP inhibitor. If you have triple negative (ER-, PR-, HER2-) breast cancer, you must have received less than three prior therapies for advanced disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BGB-290, by mouth</li> <li class="seamTextUnorderedListItem">Temolozomide, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The two drugs being used in this study are temozolomide (Temodar) and BGB-290. </li> <li class="seamTextUnorderedListItem">Temodar is used to treat brain cancer. </li> <li class="seamTextUnorderedListItem">BGB-290 is a type of targeted therapy called a PARP inhibitor.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03150810' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a601250.html' target='_blank'>NIH MedlinePlus: Temozolomide</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.beigene.com/pipeline/clinical-candidates/bgb-290/' target='_blank'>Drug Company Information Page: BGB-290</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/temozolomide' target='_blank'>Cancer Research UK: Temozolomide</a> </li></ul>
68
NEAREST SITE: 1481 miles
South Texas Accelerated Research Therapeutics, LLC
San Antonio,TX
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT03875313
Telaglenastat and Talazoparib for Advanced Triple Negative Breast Cancer
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors Scientific Title
Purpose
To study the safety, best dose, and effects (good and bad) of CB-839 (Telaglenastat) when it is used along with talazoparib (Talzenna®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer who have no standard treatment options available.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CB-839 (Telaglenastat), by mouth, twice daily, ongoing</li> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, twice daily, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CB-839 (Telaglenastat) is an investigational targeted therapy that blocks an enzyme called glutaminase. </li> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®) is a type of targeted therapy called a PARP inhibitor. It is approved to treat advanced HER2 negative breast cancer in people with an inherited BRCA mutation.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03875313' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer' target='_blank'>FDA: FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/glutaminase-inhibitor-cb-839' target='_blank'>NCI Drug Dictionary: Glutaminase inhibitor CB-839</a> </li></ul>
69
NEAREST SITE: 1481 miles
NEXT Oncology /ID# 210717
San Antonio,TX
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03893955
ABBV-927 and ABBV-368 for Advanced Triple Negative Breast Cancer
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors Scientific Title
Purpose
To study the safety and effects (good and bad) of using two experimental immunotherapies, ABBV-927 and ABBV-368, together.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) that has not been treated with an immunotherapy and that did not respond to at least one systemic therapy that included a taxane.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-927, by IV</li> <li class="seamTextUnorderedListItem">ABBV-368, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-927 is an immunotherapy that gets the immune system to go after cancer cells by targeting a protein called CD40. </li> <li class="seamTextUnorderedListItem">ABBV-368 is an immunotherapy that targets OX40, which is found on certain T cells. </li> <li class="seamTextUnorderedListItem">This study is also recruiting patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03893955' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd40-agonist-monoclonal-antibody-abbv-927' target='_blank'>NCI Drug Dictionary: ABBV-927</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.abbvie.com/our-science/pipeline/abbv-368.html' target='_blank'>Drug company information page: ABBV-368</a> </li></ul>
70
NEAREST SITE: 1481 miles
NEXT Oncology /ID# 208930
San Antonio,TX
VISITS: 1 visit every month, ongoing
PHASE: I
NCT ID: NCT03821935
ABBV-151 and ABBV-181 for Advanced Triple Negative Breast Cancer
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors Scientific Title
Purpose
To investigate the safety, best dose and effects (good and bad) of ABBV-151 when it used with or without ABBV-181.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) that has been treated with at least one systemic therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of the 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-151, by IV, once a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-151, by IV, once a month, ongoing</li> <li class="seamTextUnorderedListItem">ABBV-181, by IV, once a month, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-151 is a targeted therapy that blocks a protein called GARP- TGF-β1. </li> <li class="seamTextUnorderedListItem">ABBV-181 is an experimental PD-1 inhibitor. This type of immunotherapy, called a checkpoint inhibitor, gets the immune system to see and go after cancer cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03821935' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.abbvie.com/our-science/pipeline/abbv-151.html' target='_blank'>Drug company information page: ABBV-151</a> </li><li class='seamTextUnorderedListItem'><a href='https://immuno-oncologynews.com/abbv-181/' target='_blank'>Immuno-oncology news: ABBV-181</a> </li></ul>
71
NEAREST SITE: 1481 miles
South Texas Accelerated Research Therapeutics (START)
San Antonio,TX
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT04344795
TPST-1495 Alone or With Pembrolizumab for Advanced Triple Negative Breast Cancer
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors Scientific Title
Purpose
To study the safety, effects (good and bad), and best dose of TPST-1495 alone and in combination with pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have no standard treatment options available.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TPST-1495, by mouth, twice a day, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TPST-1495, by mouth, twice a day, ongoing</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TPST-1495 is an experimental (only available in clinical trials) targeted therapy.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a checkpoint inhibitor. It gets the immune system to go after cancer cells by blocking PD-1.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is approved to treat only certain types of breast cancer. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04344795' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/EmergingMetasticBreastCancer.html' target='_blank'>Susan G. Komen: Emerging Areas in Metastatic Breast Cancer Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytruda+Pan+Tumor_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=Brand+Keyword_General&kw=keytruda&utm_kxconfid=sq7irm3mh&gclid=CjwKCAjwv4_1BRAhEiwAtMDLsqE2Q3a74MSBt-Qt-jPAPtFkWZ4hjxPY6s9hW1c5ZyCjJkFSvzZULhoCbjYQA' target='_blank'>Merck Oncology Information Page: Keytruda® (Pembrolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tempesttx.com/file.cfm/33/docs/2019-sitc-poster-p311.pdf' target='_blank'>Drug Company Information Page: TPST-1495</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
72
NEAREST SITE: 1481 miles
Novartis Investigative Site
San Antonio,TX
VISITS: 5 visits over the first 3 weeks, then one visit every 3 weeks, ongoing
PHASE: I-II
NCT ID: NCT02829723
BLZ945 Alone or With PDR001 For Metastatic Breast (and Other) Cancer
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors Scientific Title
Purpose
To investigate whether a new type of targeted cancer drug is safe and effective when it is given alone or with an immunotherapy drug.
Who is this for?
This study has two phases: Phase 1 is for people with any type of metastatic (stage iV) breast cancer; Phase II is for people with metastatic, triple negative breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive one of the following treatments: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BLZ945</li> </ul> <p class="seamTextPara"> or </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BLZ945 and PDR001</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
-
<p class="seamTextPara"> The targeted drug being used in this study is called BLZ945. It targets a receptor called CSF1R that plays a role in tumor growth. </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This is the first study to test this new targeted drug in cancer patients. </li> <li class="seamTextUnorderedListItem">Some patients who enroll in this study will also receive an immunotherapy drug called PDR001.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02829723' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=770801' target='_blank'>NCI Drug Dictionary: PDR001</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902121/' target='_blank'>OncoImmunology: CSF1R</a> </li></ul>
73
NEAREST SITE: 1482 miles
Baylor Scott and White University Medical Center
Dallas,TX
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT04032080
LY3023414 Followed by Prexasertib in Metastatic Triple Negative Breast Cancer
Pilot Clinical Trial Of Treatment With Oral LY3023414 To Inhibit Homologous Recombination (HR) Followed By Prexasertib In Patients With Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer (ExIST) Scientific Title
Purpose
To look at the safety and effects (good and bad) of treating patients with the investigational targeted therapy LY3023414 followed by the investigational targeted therapy prexasertib.
Who is this for?
Women with metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer who have not had more than 3 chemotherapy regimens.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3023414, by mouth, twice a day, until disease progression </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">followed by:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy</li> <li class="seamTextUnorderedListItem">Prexasertib, by IV, every 2 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3023414 is a type of targeted therapy called a PI3K/mTOR inhibitor. </li> <li class="seamTextUnorderedListItem">Prexasertib is a targeted therapy that blocks checkpoint kinase1 (chk1), which plays a role in chemotherapy drug resistance.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04032080' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prexasertib' target='_blank'>NCI Drug Dictionary: Prexasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pi3k-mtor-inhibitor-ly3023414' target='_blank'>NCI Drug Dictionary: LY3023414</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.1064' target='_blank'>Journal of Clinical Oncology: Safety and tolerability of LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer</a> </li></ul>
74
NEAREST SITE: 1482 miles
Baylor University Medical Center
Dallas,TX
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT03193853
Targeted therapy followed by Chemotherapy for Metastatic Triple Negative Breast Cancer
Phase II Clinical Trial of Treatment With TAK-228 and TAK-117 to Inhibit Homologous Recombination (HR) Followed by Cisplatin and Nab Paclitaxel in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer Scientific Title
Purpose
To study the safety and effects (good and bad) of using two targeted drugs (TAK-228 and TAK-117) followed by chemotherapy.
Who is this for?
Women with triple negative metastatic (stage IV) breast cancer. Your tumor must test negative for androgen receptors. In addition, you must have already had chemotherapy (anthracycline, cyclophosphamide, and taxane).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TAK-228 and TAK-117, by mouth, until disease progression</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">followed by</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cisplatin (Paraplatin®) and nab-paclitaxel (Abraxane®), by IV, as long as benefit is shown</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The targeted drugs used in this study are TAK-228 and TAK-117. Both are mTOR inhibitors. </li> <li class="seamTextUnorderedListItem">mTOR is a kinase, a type of protein found in the body. Kinases help all cells -- both healthy and cancerous – get the energy they need. When kinases don’t act normally or are overactive, they help certain breast cancers grow. mTOR inhibitors interfere with the mTOR kinase, which stops cancer cells from getting the energy they need to grow. (Breastcancer.org)</li> <li class="seamTextUnorderedListItem">Cisplatin (Paraplatin®) and nab-paclitaxel (Abraxane®) are the chemotherapy drugs used in this study.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03193853' target='_blank'>ClinicalTrials.gov</a> </li></ul>
75
NEAREST SITE: 1482 miles
Texas Oncology-Baylor -Charles A. Sammons Cancer Center
Dallas,TX
VISITS: 1 visit every 3 weeks, ongoing
PHASE: I-II
NCT ID: NCT03094169
AVID100 in Advanced Triple Negative Breast Cancer That Tests Positive for EGFR
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin Scientific Title
Purpose
To determine the safety and effects (good and bad) of using an experimental targeted therapy called AVID100.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR-, HER2-) that has not responded to other treatment options and tests positive for EGFR over-expression.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVID100 IV, by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AVID100 is a targeted antibody-drug conjugate (ADC). </li> <li class="seamTextUnorderedListItem">It targets EGFR proteins to deliver a chemotherapy drug called maytansinoid mertansine (DM1).</li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: EGFR</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03094169' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792639' target='_blank'>NCI Drug Dictionary: AVID100</a> </li></ul>
76
NEAREST SITE: 1482 miles
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas,TX
VISITS: 1 visit every 3 weeks, ongoing
PHASE: II
NCT ID: NCT03952325
Tesetaxel and Immunotherapy in Advanced HER2- Breast Cancer
A Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC (CONTESSA TRIO) Scientific Title
Purpose
To compare the safety and effects (good and bad) of an experimental oral chemotherapy drug called tesetaxel when it is given with one of three immunotherapy drugs as well as the safety and effects of tesetaxel when it is given alone.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) who have not received prior chemotherapy for advanced disease; or people, 65 or older, who have advanced or metastatic HER2 negative breast cancer and have not received prior chemotherapy for advanced disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> <u>Cohort 1:</u> </p> <p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tesetaxel, by mouth, every 3 weeks</li> <li class="seamTextUnorderedListItem">Nivolumab, by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tesetaxel, by mouth, every 3 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab, by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tesetaxel, by mouth, every 3 weeks</li> <li class="seamTextUnorderedListItem">Atezolizumab, by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <u>Cohort 2:</u> </p> <p class="seamTextPara"> <i class="seamTextEmphasis">For over 65 years old with HER2 negative breast cancer</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tesetaxel, by mouth, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">To take part in the first cohort, you must have advanced (some stage III) or metastatic (stage IV) <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer (ER-, PR- and HER2-) and have not received prior chemotherapy for advanced disease. </li> <li class="seamTextUnorderedListItem">To be part of the second cohort, you must be age 65 or older, have advanced or metastatic HER2 negative breast cancer, and have not received prior chemotherapy for advanced disease. </li> <li class="seamTextUnorderedListItem">In the first cohort, this study is comparing the safety and effects (good and bad) of an experimental oral chemotherapy drug called tesetaxel when it is given with one of three immunotherapy drugs. </li> <li class="seamTextUnorderedListItem">In the second cohort, the study is investigating the safety and effects (good and bad) of tesetaxel when it is given alone. </li> <li class="seamTextUnorderedListItem">The three immunotherapy drugs being used in this study are nivolumab (Opdivo®), pembrolizumab (Keytruda®), and atezolizumab (Tecentriq®). </li> <li class="seamTextUnorderedListItem">Opdivo and Keytruda are PD-1 inhibitors. They get the immune system to go after cancer cells by blocking a protein called PD-1 (programmed cell death 1). Both are approved for certain types of cancers. Their use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Tecentriq is a PD-L1 inhibitor. It gets the immune system to go after cancer cells by blocking PD-L1. </li> <li class="seamTextUnorderedListItem">Tecentriq in combination with Abraxane is an FDA-approved treatment for metastatic <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03952325' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ascopost.com/issues/july-25-2018/oral-taxane-shows-strong-activity-and-good-tolerability-in-metastatic-breast-cancer/' target='_blank'>ASCO post: Oral Taxane Shows Strong Activity and Good Tolerability in MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/peer-exchange/unmet-needs-mbc/tesetaxel-an-oral-taxane-for-hr-positive-mbc' target='_blank'>OncLive: Tesetaxel: An Oral Taxane for HR-Positive mBC</a> </li></ul>
77
NEAREST SITE: 1506 miles
HCA Midwest Division
Kansas City,MO
VISITS: 2 visits every 3 weeks
PHASE: III
NCT ID: NCT03371017
Atezolizumab plus Chemotherapy for Early Relapsing Recurrent Triple Negative Breast Cancer
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer Scientific Title
Purpose
To determine the safety and effects (good and bad) of giving chemotherapy with an immunotherapy agent to giving chemotherapy alone for advanced breast cancer.
Who is this for?
People with triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer. You must not have received any prior anti-cancer therapy for stage III or stage IV breast cancer. Your cancer must have progressed within 1 year from receiving treatment for early stage breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Immunotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) by IV, once every 3 weeks </li> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®) by IV, twice every 3 weeks </li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, twice every 3 weeks </li> <li class="seamTextUnorderedListItem">Capacitabine (Xeloda®), by mouth, daily, for 2 weeks, followed by a 7-day rest period </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Placebo</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo by IV, once every 3 weeks </li> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®) by IV, twice every 3 weeks </li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, twice every 3 weeks </li> <li class="seamTextUnorderedListItem">Capacitabine (Xeloda®), by mouth, daily, for 2 weeks, followed by a 7-day rest period</li></ul>
-
<p class="seamTextPara"> The immunotherapy drug being used in this study is atezolizumab (Tecentriq®). </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The chemotherapy drugs used in this study are gemcitabine (Gemzar®), carboplatin (Paraplatin®) and capecitabine (Xeloda®). </li> <li class="seamTextUnorderedListItem">Gemzar is a chemotherapy drug used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">Paraplatin is a platinum-based chemotherapy drug that is commonly used to treat <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer. </li> <li class="seamTextUnorderedListItem">Xeloda is commonly used to treat metastatic breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03371017' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/immunotherapy/what' target='_blank'>Breastcancer.org: What is Immunotherapy?</a> </li></ul>
78
NEAREST SITE: 1615 miles
Mayo Clinic
Rochester,MN
VISITS: 1 visit per month, ongoing
PHASE: II
NCT ID: NCT03941730
Estradiol in Advanced Triple Negative & ER-Low Tumors that Test Positive for ER Beta
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer Scientific Title
Purpose
To study the effects (good and bad) of estradiol in the subset of triple negative and ER-Low tumors that test positive for ER beta.
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer whose tumor tests positive for estrogen receptor beta (ER beta).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Estradiol, by mouth, 3 times a day</li> <li class="seamTextUnorderedListItem">2 biopsies (at the start of treatment and after 1 month)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Early studies suggest that estradiol--a type of estrogen--slows the growth of tumors that are ER-beta positive.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ER beta</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03941730' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Estrogen_receptor_beta' target='_blank'>Wikipedia: Estrogen receptor beta</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.drugs.com/estradiol.html' target='_blank'>Drugs.com: Estradiol</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/centers-programs/cancer-research/research-programs/womens-cancer-program/breast-cancer-spore/research-projects/therapeutic-targeting-estrogen-receptor-beta-triple-negative-breast-cancer' target='_blank'>Mayo Clinic: Therapeutic Targeting Estrogen receptor-beta in TNBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/30338035' target='_blank'>Journal Abstract: Estrogen receptor-beta is a potential target for TNBC</a> </li></ul>
79
NEAREST SITE: 1615 miles
Mayo Clinic
Rochester,MN
VISITS: 1 visit every 2-3 weeks, ongoing
PHASE: I-II
NCT ID: NCT03106415
Pembrolizumab and Binimetinib for Advanced Triple Negative or ER-Low Breast Cancer
Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer Scientific Title
Purpose
To study the safety and effectiveness of using an immunotherapy along with a targeted therapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer. You must have received no more than 3 prior therapies for metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda ®), by IV, once every 2-3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Binimetinib (MEK162), by mouth, daily, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. </li> <li class="seamTextUnorderedListItem">Keytruda® is currently approved to treat certain types cancers. </li> <li class="seamTextUnorderedListItem">Binimetinib (MEK162) is a type of targeted therapy called an MEK inhibitor.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03106415' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com' target='_blank'>Merck Oncology Information Page: Keytruda</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.arraybiopharma.com/product-pipeline/binimetinib/' target='_blank'>Drug Company Information Page: Binimetinib</a> </li></ul>
80
NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT02926690
OTS167PO: A Targeted Therapy for Advanced Triple Negative or ER-Low Breast Cancer
A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer Scientific Title
Purpose
To determine the safety and effects (good and bad) of using the experimental targeted therapy OTS167PO.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast (ER-, PR-, HER2-) or ER-Low (1%-10%) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OTS167PO </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">The targeted therapy used in this trial is OTS167PO. It is a MELK inhibitor. </li> <li class="seamTextUnorderedListItem">It is an experimental therapy. This means it is only available in clinical trials. </li> <li class="seamTextUnorderedListItem">Targets or mutations: MELK</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02926690' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.oncotherapy.co.jp/en/research-development/drug-discovery-research/melk-inhibitor/' target='_blank'>Drug Company Information Page: OTS167</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/melk-inhibitor-ots167' target='_blank'>NCI Drug Dictionary: OTS167</a> </li></ul>
81
NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03654547
TT-00420 For Advanced Triple Negative or ER-Low Breast Cancer
A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers Scientific Title
Purpose
To study the best dose, safety, and effects (good and bad) of an investigational targeted therapy called TT-00420.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer that has not responded to other treatments.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TT-00420, by mouth, once daily, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">TT-00420 blocks the growth of the new blood vessels tumors need to grow and targets tumor inflammation.</li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03654547' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://abstracts.asco.org/239/AbstView_239_266885.html' target='_blank'>ASCO abstract: TT-00420</a> </li></ul>
82
NEAREST SITE: 1643 miles
Houston Methodist Hospital
Houston,TX
VISITS: 5 visits a week, every 3 weeks, ongoing
PHASE: I-II
NCT ID: NCT02834403
L-NMMA plus Taxotere for Women with Advanced Triple Negative or ER-Low Breast Cancer
Clinical Phase Ib Trial of L-NMMA Plus Docetaxel in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients Scientific Title
Purpose
To determine the best dose, safety and effects of L-NMMA when it is given with chemotherapy.
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer. If you are stage III, you must have received at least 3 types of chemotherapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">L-NMMA, by IV, daily for 5 days, every 3 weeks</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), by IV, once every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws</li> <li class="seamTextUnorderedListItem">Biopsies</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">L-NMMA targets the NOS (nitric oxide synthase) inhibitor.</li> <li class="seamTextUnorderedListItem">The chemotherapy being used is docetaxel (Taxotere®).</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02834403' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://cancerres.aacrjournals.org/content/77/13_Supplement/CT037' target='_blank'>AACR Abstract: L-NMMA</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
83
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: 4 visits every 6 weeks, ongoing
PHASE: I
NCT ID: NCT03579472
M7824 and Halaven for Metastatic Triple Negative or ER-Low Breast Cancer
A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC) Scientific Title
Purpose
To find the best dose of M7824 to use with eribulin (Halaven).
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">M7824, by IV, weekly, for 3 out of every 6 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Eribulin, by IV, weekly, for 4 out of every 6 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">M7824 is an investigational immunotherapy drug. </li> <li class="seamTextUnorderedListItem">It gets immune cells to see cancer cells by blocking PD-L1 and TGF-beta. </li> <li class="seamTextUnorderedListItem">Halaven is used to treat patients who have already had at least two other anticancer medicines for their metastatic breast cancer and who have already been treated with an anthracycline and a taxane for either early or advanced breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03579472' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://immuno-oncologynews.com/io-m7824/' target='_blank'>Immuno-Oncology News: M7824</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.halaven.com/metastatic-breast-cancer' target='_blank'>Drug Company Information Page: Halaven</a> </li></ul>
84
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: 1 visit every 3 weeks, ongoing
PHASE: II
NCT ID: NCT02411656
Pembrolizumab for Metastatic HER2- Inflammatory, Triple Negative, and ER-Low Breast Cancer
A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer Who Have Received Prior Chemotherapy With Clinical Response Scientific Title
Purpose
To look at the safety and effects (good and bad) of using pembrolizumab (Keytruda®).
Who is this for?
People with metastatic (stage IV) HER2 negative inflammatory, triple negative (ER-, PR-, HER2-), or ER-Low (1%-10%) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is an immunotherapy that helps the body's immune system slow or stop cancer cell growth by blocking a protein known as programmed cell death receptor-1 (PD-1).</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02411656' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytruda+Pan+Tumor_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=Brand+Keyword_General&kw=keytruda&utm_kxconfid=sq7irm3mh&gclid=CjwKCAjwy7vlBRACEiwAZvdx9jIPFQgWidLA-C5wT1MzjtITa1lJzO4axMQhgd1rro0RP5g40-abvxoCQlYQA' target='_blank'>Merck Drug Information Page: Keytruda</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pembrolizumab' target='_blank'>NCI Drug Dictionary: Pembrolizumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/Inflammatory-Breast-Cancer.html' target='_blank'>Susan G. Komen: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/TripleNegativeBreastCancer.html' target='_blank'>Susan G. Komen: Triple Negative Breast Cancer</a> </li></ul>
85
NEAREST SITE: 1643 miles
Houston Methodist Cancer Center
Houston,TX
VISITS: 1 visit daily for 2 weeks, then every 3 weeks ongoing
PHASE: II
NCT ID: NCT03004183
Vaccine & Radiation Therapy Then Immunotherapy For Advanced Triple Negative Breast Cancer
Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab (STOMP) Scientific Title
Purpose
To investigate the safety and effects (good and bad) of receiving a vaccine, then SBRT radiation therapy (stereotactic body radiation therapy), then the immunotherapy pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have no other treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ADV/HSV-tk, by injection, once</li> <li class="seamTextUnorderedListItem">followed by valacyclovir (anti-viral drug), by mouth, daily, for 2 weeks</li> <li class="seamTextUnorderedListItem">Stereotactic body radiation therapy (SBRT), 5 sessions over 2 weeks</li> <li class="seamTextUnorderedListItem">followed by pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The vaccine is called ADV/HSV-tk. It is given along with the anti-viral drug valacyclovir. </li> <li class="seamTextUnorderedListItem">The immunotherapy used in this study is pembrolizumab (Keytruda®). It is approved to treat certain types of cancers. </li> <li class="seamTextUnorderedListItem">This study is also enrolling people with advanced non-small cell lung cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03004183' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/aglatimagene-besadenovec' target='_blank'>NCI Drug Dictionary: ADV/HSV-tk</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/valacyclovir-hydrochloride' target='_blank'>NCI Drug Dictionary: Valacyclovir</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/treatment-options/stereotactic-body-radiation-therapy.html' target='_blank'>MD Anderson Cancer Center: SBRT</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nejm.org/doi/full/10.1056/NEJMoa1910549' target='_blank'>New England Journal of Medicine: Pembrolizumab for Early Triple-Negative Breast Cancer</a> </li></ul>
86
NEAREST SITE: 1643 miles
Kymab investigator site 1101
Houston,TX
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT03829501
KY1044 and Immunotherapy Atezolizumab for Advanced Triple Negative Breast Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies Scientific Title
Purpose
To study the safety, effects (good and bad), and anti-cancer activity of using immunotherapy KY1044 alone or with the PD-1 inhibitor Tecentriq® (atezolizumab).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-,PR-,HER2-) breast cancer that has not responded to other treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Monotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">KY1044</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Combination Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">KY1044</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">KY1044 stimulates immune cells to go after and kill cancer cells. </li> <li class="seamTextUnorderedListItem">It also kills the T regulatory cells that keep immune cells from killing the cancer cells.</li> <li class="seamTextUnorderedListItem">Tecentriq® (atezolizumab) is a type of immunotherapy called a PD-L1 (programmed cell death-ligand 1) inhibitor. </li> <li class="seamTextUnorderedListItem">It is approved to treat advanced <span class="highlight">triple</span> <span class="highlight">negative</span> breast cancer, as well as certain types of bladder and lung cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03829501' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.kymab.com/news-and-events/news/2017/nov/8/ky1044-anti-icos-antibody-sitc/' target='_blank'>Drug Sponsor Site: KY1044</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertherapyadvisor.com/home/news/conference-coverage/american-society-of-clinical-oncology-asco/asco-2018/first-in-class-icos-agonist-alone-or-in-combination-may-be-effective-for-advanced-cancer/' target='_blank'>StatNews: Tecentriq approval for breast cancer</a> </li></ul>
87
NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX
VISITS: Weekly visits
PHASE: I
NCT ID: NCT04429542
BCA101 for Metastatic Triple Negative Breast Cancer That Tests Positive for EGFR
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-Driven Advanced Solid Tumors Scientific Title
Purpose
To study the safety, anti-cancer activity, and effects (good and bad) of the targeted therapy BCA101.
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer that tests positive for EGFR amplification and who have no other treatment options available.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BCA101, by IV, once a week, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BCA101 targets the EGFR and TGFβ pathways. </li> <li class="seamTextUnorderedListItem">It is an experimental targeted therapy, this means it is only available in clinical trials.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of metastatic cancer. </li> <li class="seamTextUnorderedListItem">Targets or mutations: EGFR</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04429542' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://europepmc.org/article/med/27648353' target='_blank'>Journal Article Abstract: A Perspective on Anti-EGFR Therapies Targeting Triple Negative Breast Cancer.</a> </li></ul>
88
NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT04432857
AN0025 and Pembrolizumab for Advanced Triple Negative Breast Cancer
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Scientific Title
Purpose
To study the safety, anti-cancer activity, and side effects of combining the experimental targeted therapy AN0025 with the immunotherapy pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have received no more than 3 prior therapies for advanced disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AN0025, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AN0025 is an experimental targeted therapy. This means it is only available in clinical trials.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor/checkpoint inhibitor. It is approved for use in other cancers but its use for breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04432857' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.adlainortye.com/en_product.php' target='_blank'>Adlai Nortye Drug Information Page: AN0025</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/keytruda-plus-chemo-better-than-chemo-alone-for-some' target='_blank'>Breastcancer.org: Keytruda Plus Chemotherapy Offers More Benefits Than Chemo Alone as First Treatment for Metastatic Triple-Negative Breast Cancer With High Levels of PD-L1</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytruda+Pan+Tumor+KEYTRUDA+ONLY_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=Brand+Keyword_General&kw=keytruda&utm_kxconfid=sq7irm3mh&gclid=Cj0KCQjwpNr4BRDYARIsAADIx9zN_JT9uThoV9MYlllBnCVVYDzP8fCogm1trpDps_D9ZqW' target='_blank'>Merck Oncology Drug Information Page: Keytruda® (Pembrolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
89
NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX
VISITS: 2 visits every 3 weeks, ongoing
PHASE: I-II
NCT ID: NCT03992131
Rubraca & Sacituzumab Govitecan to Treat Metastatic Triple Negative or BRCA+ Tumors
SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor Scientific Title
Purpose
To study the safety and effects (good and bad) of the combination of rucaparib (Rubraca®) and sacituzumab govitecan.
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer that has been treated with at least one standard therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rucaparib (Rubraca®), by mouth, twice daily, ongoing</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (IMMU-132), by IV, 2 times every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rubraca is a PARP inhibitor approved to treat recurrent ovarian, fallopian tube, and primary peritoneal cancer. </li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan is a type of cancer therapy called an antibody-drug conjugate. It uses an antibody that targets cancer cells to deliver the drug SN-38 directly to these cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03992131' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rucaparib-phosphate' target='_blank'>NCI Drug Dictionary: Rucaparib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.clovisoncology.com/pipeline/rucaparib/' target='_blank'>Drug company information site: Rucaparib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sacituzumab-govitecan' target='_blank'>NCI Drug Dictionary: Sacituzumab govitecan</a> </li></ul>
90
NEAREST SITE: 1643 miles
Novartis Investigative Site
Houston,TX
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03549000
NZV930, PDR001 and NIR178 Immunotherapies in Advanced Triple Negative Breast Cancer
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies. Scientific Title
Purpose
To compare the safety and effects (good and bad) of NZV930 alone or in combination with PDR001 and/or NIR178.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) that has not responded to other treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NZV930, by IV </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NZV930, by IV </li> <li class="seamTextUnorderedListItem">PDR001, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NZV930, by IV</li> <li class="seamTextUnorderedListItem">NIR178, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NZV930, by IV</li> <li class="seamTextUnorderedListItem">PDR001, by IV</li> <li class="seamTextUnorderedListItem">NIR178, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i> </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">2 biopsies (a new tumor biopsy at screening and during treatment)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NZV930 is an investigational targeted therapy that blocks the CD73 protein. Blocking this protein allows T cells and other immune cells to attack the tumor. </li> <li class="seamTextUnorderedListItem">PDR001 is an investigational immunotherapy. It is a type of immunotherapy called a PD-1 inhibitor. </li> <li class="seamTextUnorderedListItem">NIR178 is an investigational immunotherapy. It is an immune checkpoint inhibitor that gets the immune system to attack cancer cells by blocking the adenosine A2A receptor (A2AR).</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03549000' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.surfaceoncology.com/our-science/srf373-nzv930-cd73-antibody/' target='_blank'>Sponsor site: AZV930</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/spartalizumab' target='_blank'>NCI Drug Dictionary: PDR001</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793151' target='_blank'>NCI Drug Dictionary: NIR178</a> </li></ul>
91
NEAREST SITE: 1643 miles
MD Anderson Cancer Center
Houston,TX
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT04234113
SO-C101 (Immunotherapy) Alone or With Pembrolizumab In Advanced Triple Negative Breast Cancer
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors Scientific Title
Purpose
To study the safety, best dose, anti-tumor activity and effects (good and bad) of the experimental immunotherapy drug SO-C101 (RLI-15) when it is given alone or in combination with pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have no standard treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SO-C101</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SO-C101</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SO-C101 (RLI-15) is a new type of immunotherapy that works by getting immune cells called natural killer cells to kill cancer cells. </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. It is approved to treat certain types of cancers. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04234113' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sotio.com/pipeline/so-c101' target='_blank'>Drug Company Information Page: SO-C101 (RLI-15)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytruda+Pan+Tumor_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=Brand+Keyword_General&kw=keytruda&utm_kxconfid=sq7irm3mh&gclid=CjwKCAiA1rPyBRAREiwA1UIy8AIFO2xkZ72nv59oRzgEL2_j5xbdlfT_f9w1NuFPTrkeUqYvN9yqxxoCBOYQA' target='_blank'>Merk Oncology Drug Information: Keytruda® (Pembrolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerhealth.com/article/immunotherapies-show-mixed-results-triplenegative-breast-cancer' target='_blank'>Cancer Health: Immunotherapies Show Mixed Results for Triple-Negative Breast Cancer</a> </li></ul>
92
NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03207529
Alpelisib & Enzalutamide in Advanced Breast Cancer That Tests AR+ and PTEN+
Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer Scientific Title
Purpose
To determine the best dose, safety, and effects (good and bad) of alpelisib (Piqray®) when it is used along with enzalutamide (Xtandi®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER positive and/or PR positive) or triple negative (ER-, PR-, HER2-) breast cancer that tests AR-positive and PTEN-positive and who have received at least one standard therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Enzalutamide (Xtandi®), by mouth, daily</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Piqray is a targeted therapy that inhibits PI3K. It is approved to treat advanced hormone receptor positive, HER2 negative breast cancer in patients with a tumor that has a PIK3CA mutation. </li> <li class="seamTextUnorderedListItem">Xtandi is an oral drug that targets the androgen receptor (AR). It is approved to treat advanced prostate cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: AR (androgen receptor), PTEN</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03207529' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.novartis.com/news/media-releases/novartis-investigational-byl719-alpelisib-plus-fulvestrant-consistently-improved-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-new-solar-1-analyses' target='_blank'>Novartis Press Release: BYL719 (alpelisib) plus fulvestrant for PIK3CA mutated HR+/HER2- advanced breast cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/enzalutamide' target='_blank'>NCI Drug Dictionary: Enzalutamide</a> </li></ul>
93
NEAREST SITE: 1655 miles
University of Iowa Hospital and Clinics
Iowa City,IA
VISITS: Weekly visits, ongoing
PHASE: I-II
NCT ID: NCT03911973
Gedatolisib and Talazoparib in Advanced Triple Negative or Inherited BRCA 1/2+, HER2 Negative Breast Cancer
Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337 Scientific Title
Purpose
To determine the safety, best dose, and effects (good and bad) of gedatolisib when it is used in combination with talazoparib (Talzenna®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer whose cancer is triple negative (ER-, PR-, HER2-) or they have an inherited BRCA 1 or BRCA 2 mutation and their cancer is HER2 negative (HER2-).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by IV, once a week </li> <li class="seamTextUnorderedListItem">Gedatolisib, by IV, once a day</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gedatolisib is an experimental targeted therapy that works by blocking two proteins, called PI3K and mTOR, that help tumors grow. </li> <li class="seamTextUnorderedListItem">Talzenna is a type of targeted therapy called a PARP inhibitor. It is approved to treat HER2 negative advanced or metastatic breast cancer in people with an inherited BRCA mutation.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03911973' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/web-exclusives/fda-approves-talazoparib-for-brcamutated-her2negative-breast-cancer' target='_blank'>OncLive: FDA Approves Talazoparib for BRCA-Mutated, HER2- Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pfizer.com/files/news/asco/Pfizer_IO_GetaPI3KFactSheet.pdf' target='_blank'>Pfizer Oncology Information Page: Gedatolisib</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
94
NEAREST SITE: 1754 miles
Cancer Care Specialists of Central Illinois-Swansea
Swansea,IL
VISITS: 1 visit every 3 weeks, for up to 2 years
PHASE: II
NCT ID: NCT04024800
AE37 Vaccine and Immunotherapy Pembrolizumab in Metastatic Triple Negative or ER-Low Breast Cancer
A Phase II Clinical Trial of Pembrolizumab in Combination With the AE37 Peptide Vaccine in Patients With Metastatic Triple-Negative Breast Cancer (NSABP FB-14) Scientific Title
Purpose
To study the safety, best dose and effects (good and bad) of an AE37 peptide vaccine (AE37) when it is given along with the PD-1 inhibitor pembrolizumab (Keytruda®).
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) who have been treated with at least one line of therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AE37 Peptide vaccine, by injection, once every 3 weeks, for 4 months</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda® ), by IV, once every 3 weeks, for up to 2 years</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">The vaccine is a type of immunotherapy. It gets the immune cells to see and kill cancer cells. </li> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy called a PD-1 inhibitor. It gets the immune system to see and kill cancer cells by blocking a checkpoint called PD-1. It is approved to treat metastatic breast tumors that genomic testing has shown are microsatellite instability-high (MSI-H) or have a DNA mismatch repair deficiency (dMMR).</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04024800' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/news/pembrolizumab-and-chemotherapy-met-primary-endpoint-in-phase-iii-tnbc-trial' target='_blank'>Targeted Oncology: Pembrolizumab and Chemotherapy Met Primary Endpoint in Phase III TNBC Trial</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ae37-peptide-gm-csf-vaccine' target='_blank'>NCI Drug Dictionary: AE37 peptide</a> </li></ul>
95
NEAREST SITE: 1857 miles
University of Chicago
Chicago,IL
VISITS: 1 visit a week, ongoing
PHASE: II
NCT ID: NCT02788981
Abraxane & Mifepristone in Advanced Triple Negative or ER-Low Breast Cancer that is Glucocorticoid Receptor Positive
A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer Scientific Title
Purpose
To determine the safety and effects (good and bad) of using chemotherapy in combination with the anti-progesterone therapy mifepristone.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- HER2-) or ER-Low (1%-10% ER) breast cancer that tests positive for glucocorticoid receptors.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mifepristone, by mouth, daily</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®), by IV, weekly (3 weeks on, 1 week off)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by mouth, daily</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®), by IV, weekly (3 weeks on, 1 week off)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">The chemotherapy drug being used in this study is nab-paclitaxel (Abraxane®). It is approved to treat advanced breast cancer. </li> <li class="seamTextUnorderedListItem">Targets or mutations: glucocorticoid receptors</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02788981' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860283/' target='_blank'>Clinical Cancer Research: Glucocorticoid receptor antagonism for TNBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.abraxanepro.com' target='_blank'>Drug Company Information Page: Abraxane</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Mifepristone' target='_blank'>Wikipedia: Mifepristone</a> </li></ul>
96
NEAREST SITE: 1946 miles
IU Simon Cancer Center
Indianapolis,IN
VISITS: Weekly visits, ongoing
PHASE: I
NCT ID: NCT03243331
Gedatolisib plus PTK7-ADC for Metastatic Triple Negative Breast Cancer
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer Scientific Title
Purpose
To investigate the safety and effects (good and bad) of using two investigational drugs to treat metastatic triple negative breast cancer.
Who is this for?
People with metastatic (stage IV) breast cancer that is triple negative. You must have received at least 1 prior chemotherapy regimen for metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gedatolisib, by IV, weekly (3 weeks on, 1 week off), ongoing </li> <li class="seamTextUnorderedListItem">PTK7-ADC (PF-06647020), by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The two drugs are gedatolisib and PTK7-ADC. </li> <li class="seamTextUnorderedListItem">Gedatolisib is a targeted therapy that works by blocking PI3K and mTOR kinase proteins, which play a role in the cellular pathways that help tumors grow. </li> <li class="seamTextUnorderedListItem">PTK7-ADC (PF-06647020) targets a protein called PTK7, which is often found on cancer cells. </li> <li class="seamTextUnorderedListItem">It is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a drug that can kill these cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03243331' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.pfizer.com/files/news/asco/Pfizer_IO_GetaPI3KFactSheet.pdf' target='_blank'>Pfizer: Gedatolisib</a> </li></ul>
97
NEAREST SITE: 1946 miles
Indiana University Health Melvin Bren Simon Cancer Center
Indianapolis,IN
VISITS: 1 visit every 3 weeks, ongoing
PHASE: II
NCT ID: NCT03206203
Carboplatin plus Atezolizumab for Metastatic Triple Negative or ER-Low Breast Cancer
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer Scientific Title
Purpose
To compare the anti-cancer activity of giving the chemotherapy carboplatin (Paraplatin®) alone to giving it in combination with the immunotherapy atezolizumab (Tecentriq®).
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer. You must not have received more than one prior chemotherapy for metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®) is the chemotherapy drug used in this study. </li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is the immunotherapy drug used in this study. It is an anti-PDL1 medicine.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03206203' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tecentriq.com' target='_blank'>Genentech Information Page: Atezolizumab</a> </li></ul>
98
NEAREST SITE: 1946 miles
Indiana University
Indianapolis,IN
VISITS: 1 visit a week, ongoing
PHASE: II
NCT ID: NCT02755272
Keytruda with Chemotherapy for Metastatic Triple Negative or ER-Low Breast Cancer
A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in Combination With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Scientific Title
Purpose
To study the anti-cancer activity of giving the PD-1 inhibitor pembrolizumab (Keytruda®) immunotherapy in combination with chemotherapy.
Who is this for?
Women with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10%) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®) and gemcitabine (Gemzar®) by IV, once a week, 2 weeks on 1 week off</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®) and gemcitabine (Gemzar®) by IV, once a week, 2 weeks on 1 week off</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a checkpoint inhibitor. It gets the immune system to go after cancer cells by blocking PD-1.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is approved to treat certain types of cancer. Its use in breast cancer is considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02755272' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytruda+Pan+Tumor_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=Brand+Keyword_General&kw=keytruda&utm_kxconfid=sq7irm3mh&gclid=CjwKCAjwy7vlBRACEiwAZvdx9jIPFQgWidLA-C5wT1MzjtITa1lJzO4axMQhgd1rro0RP5g40-abvxoCQlYQA' target='_blank'>Merck Information Page: Keytruda</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/EmergingMetasticBreastCancer.html' target='_blank'>Susan G. Komen: Emerging Areas in Metastatic Breast Cancer Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
99
NEAREST SITE: 1946 miles
Indiana University Melvin & Bren Simon Cancer Center
Indianapolis,IN
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT04134884
ASTX727 and Talazoparib in Advanced HER2 Negative Breast Cancer
A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer Scientific Title
Purpose
To study the safety and effects (good and bad) of using the PARP inhibitor Talazoparib (Talzenna®) along with the targeted therapy ASTX727.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer who have already received chemotherapy or a CDK 4/6 inhibitor with hormone therapy for metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">ASTX727, by mouth, first 5 days of every cycle (28 days), ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®) is a type of drug called a PARP inhibitor. It works by preventing the PARP protein from repairing damaged DNA in tumor cells.</li> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®) is approved to treat advanced or metastatic HER2 negative (HER2-) breast cancer in people with an inherited BRCA 1 or BRCA 2 mutation.</li> <li class="seamTextUnorderedListItem">ASTX727 is an investigational targeted therapy that is only available in clinical trials.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04134884' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/talzenna' target='_blank'>Breastcancer.org: Talazoparib (Talzenna®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.talzenna.com/?source=google&HBX_PK=s_+pfizer++talazoparib&skwid=43700051780428716' target='_blank'>Pfizer Oncology Drug Information Page: Talzenna® (Talazoparib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.curetoday.com/expertconnections/parp-inhibition-brca-mutated-breast-cancer/benefit-of-parp-inhibitors-in-brca-positive-breast-cancer' target='_blank'>Cure Today: Benefit of PARP Inhibitors in BRCA+ Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cda-inhibitor-e7727-decitabine-combination-agent-astx727' target='_blank'>NCI Drug Dictionary: ASTX727 (CDA Inhibitor E7727)</a> </li><li class='seamTextUnorderedListItem'><a href='https://astx.com/research-development/clinical-pipeline/astx727-oral-dnmt-inhibitor-hematological-malignancies/' target='_blank'>Drug Company Information Page: ASTX727 (Cedazuridine and Decitabine)</a> </li></ul>
100
NEAREST SITE: 1958 miles
Vanderbilt University/Ingram Cancer Center
Nashville,TN
VISITS: Visits weekly, ongoing
PHASE: I
NCT ID: NCT02672475
Galunisertib and Taxol for Metastatic Triple Negative Breast Cancer
A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer Scientific Title
Purpose
To evaluate the best dose and safety of galunisertib and Taxol for treating patients with metastatic triple negative breast cancer that is also androgen-receptor negative.
Who is this for?
People diagnosed with metastatic (stage IV) triple negative breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> All participants will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Galunisertib (LY2157299), by mouth, twice daily, 3 weeks on, 1 week off</li></ul>
-
<p class="seamTextPara"> Paclitaxel (Taxol®) is a chemotherapy drug routinely used to treat advanced breast cancer. </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Galunisertib (LY2157299) is a new type of targeted therapy. It works by blocking a protein called TGF-beta 1 kinase.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02672475' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/ct2/show/NCT02672475?term=NCT02672475&rank=1' target='_blank'>ClinicalTrials.gov: Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.onclive.com/publications/oncology-live/2014/august-2014/targeting-the-androgen-receptor-new-hope-for-aggressive-forms-of-prostate-and-breast-cancer/3' target='_blank'>OncLive: Targeting Angrogen Receptor</a> </li></ul>
101
NEAREST SITE: 1959 miles
START Midwest
Grand Rapids,MI
VISITS: At least 1 visit every 3 weeks
PHASE: I-II
NCT ID: NCT03917381
Immunotherapy GEN1046 in Metastatic Triple Negative Breast Cancer
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors Scientific Title
Purpose
To find the best dose and study the effects (good and bad) of the experimental immunotherapy GEN1046.
Who is this for?
People with metastatic (stage IV), triple negative (ER-, PR-, HER2-) breast cancer who have no standard treatment options available.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive GEN1046, by IV, every 3 weeks</p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of solid tumors.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03917381' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.genmab.com/product-pipeline/products-in-development' target='_blank'>Drug Company Information Page: GEN1046</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2018/10/03/mbc-news-4/' target='_blank'>Metastatic Trial Talk: Immunotherapy & Metastatic Breast Cancer</a> </li></ul>
102
NEAREST SITE: 1959 miles
Novartis Investigative Site
Nashville,TN
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03742349
Four Immunotherapy Combinations in Advanced Triple Negative Breast Cancer
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer Scientific Title
Purpose
To study the safety, best dose and effects (good and bad) of spartalizumab and LAG525 when they are used in combination with NIR178, capmatinib, MCS110, or canakinumab.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have not received more than two prior lines of chemotherapy, including neoadjuvant or adjuvant chemotherapy; and have had a taxane-based chemotherapy as neoadjuvant or metastatic treatment.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Spartalizumab (PDR001), by IV</li> <li class="seamTextUnorderedListItem">LAG525, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">with 1 of the following 4 drugs: </i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NIR178, by mouth</li> <li class="seamTextUnorderedListItem">Capmatinib (INC280), by mouth</li> <li class="seamTextUnorderedListItem">MCS110 (INC280), by IV</li> <li class="seamTextUnorderedListItem">Canakinumab (ACZ885), by injection</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Spartalizumab is an investigational PD-1 immune checkpoint inhibitor. </li> <li class="seamTextUnorderedListItem">LAG525 is an investigational immune checkpoint inhibitor that targets LAG-3. </li> <li class="seamTextUnorderedListItem">NIR178 is an investigational immunotherapy. </li> <li class="seamTextUnorderedListItem">Capmatinib is a targeted therapy that blocks c-Met, which plays a role in cancer cell growth.</li> <li class="seamTextUnorderedListItem">MCS110 is an investigational immunotherapy that targets M-CSF. </li> <li class="seamTextUnorderedListItem">Canakinumab is an investigational monoclonal antibody that targets human interleukin-1 beta (IL-1b), which plays a role in inflammation.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03742349' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/spartalizumab' target='_blank'>NCI Drug Dictionary: Spartalizumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-lag-3-monoclonal-antibody-lag525' target='_blank'>NCI Drug Dictionary: LAG525</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/capmatinib' target='_blank'>NCI Drug Dictionary: Capmatinib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-m-csf-monoclonal-antibody-mcs110' target='_blank'>NCI Drug Dictionary: MCS110</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795723' target='_blank'>NCI Drug Dictionary: Canakinumab</a> </li></ul>
103
NEAREST SITE: 1959 miles
Sarah Cannon Research Institute Drug Ship - 3
Nashville,TN
VISITS: Number of visits unavailable
PHASE: I
NCT ID: NCT03891953
Immunotherapy DKY709 Alone or With PDR001 in Advanced Triple Negative Breast Cancer
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors Scientific Title
Purpose
To compare the safety and effects (good and bad) of DKY709 alone and in combination with PDR001.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer that has not been treated with a PD-1 or PD-L1 checkpoint inhibitor.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DKY709</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DKY709</li> <li class="seamTextUnorderedListItem">PDR001 (Spartalizumab)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DKY709 is an investigational immunotherapy. </li> <li class="seamTextUnorderedListItem">PDR001 (spartalizumab) is an investigational immunotherapy that targets PD-1 .</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03891953' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/spartalizumab' target='_blank'>NCI Drug Dictionary: Spartalizumab</a> </li></ul>
104
NEAREST SITE: 1959 miles
Sarah Cannon Research Institute
Nashville,TN
VISITS: 1 visit every 3 weeks
PHASE: I
NCT ID: NCT04157517
Immunotherapy TAK-573 for Advanced Triple Negative Breast Cancer
An Open-Label, Dose-Escalation Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-573 in Adult Patients With Metastatic Solid Tumors Scientific Title
Purpose
To study the safety, effects (good and bad), and anti-cancer activity of the immunotherapy TAK-573.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TAK-573, by IV, every 3 weeks, ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TAK-573 is an experimental immunotherapy. This means it is only available in clinical trials.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04157517' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd38-targeted-igg4-attenuated-ifna-tak-573' target='_blank'>NCI Drug Dictionary: TAK-573</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.takeda.com/49ef0c/siteassets/system/investors/report/quarterlyannouncements/fy2018/1_oncology_e.pdf' target='_blank'>Takeda Drug Information Page: TAK-573</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
105
NEAREST SITE: 2010 miles
University of Alabama at Birmingham
Birmingham,AL
VISITS: After first 2 weeks of treatment, weekly visits, ongoing
PHASE: I
NCT ID: NCT01920061
SGN-LIV1A in HER2-Negative Metastatic Breast Cancer
A Phase 1B Open-Label Three-Arm Multi-Center Study To Assess The Safety And Tolerability Of PF-05212384 (PI3K/MTor Inhibitor) In Combination With Other Anti-Tumor Agents Scientific Title
Purpose
To assess the safety, highest tolerable dose and anti-tumor activity of SGN-LIV1A .
Who is this for?
Women with stage III or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer or metastatic (stage IV) HER2 negative, estrogen receptor positive breast cancer that can no longer be treated with a hormone therapy.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> Participants will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Advanced Breast Cancer</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-05212384 by IV once a week</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®) by IV every 3 weeks </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: <span class="highlight">Triple</span>-<span class="highlight">Negative</span> Breast Cancer</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-05212384 by IV once a week</li> <li class="seamTextUnorderedListItem">Cisplatin (Platinol®) by IV every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: HER2-positive Breast Cancer</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-05212384 by IV once a week</li> <li class="seamTextUnorderedListItem">Dacomitinib (PF-00299804) by mouth daily</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Antibody-drug conjugates (ADCs) are cancer therapies that combine an antibody that targets cancer cells with a drug that can kill cancer cells. Because the antibody only targets cancer cells, the drug does not kill normal cells, making it less likely to cause side effects. </li> <li class="seamTextUnorderedListItem">SGN-LIV1A is an ADC that targets LIV-1 (SLC39A6), a protein that is expressed by most breast cancer cells, and delivers a cancer drug called monomethyl auristatin E.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01920061' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.pfizer.com/files/news/asco/dacomitinib_fact_sheet.pdf' target='_blank'>Pfizer: Dacomitinib</a> </li><li class='seamTextUnorderedListItem'><a href='http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C91732' target='_blank'>NCI Thesaurus: PI3 Kinase/mTOR inhibitor</a> </li></ul>
106
NEAREST SITE: 2088 miles
Karmanos Cancer Institute
Detroit,MI
VISITS: Number of visits unavailable
PHASE: I-II
NCT ID: NCT02632448
LY2880070 in Advanced Triple Negative Breast Cancer
A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer Scientific Title
Purpose
To study the safety and effects (good and bad) of an investigational drug called LY2880070.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY2880070, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY2880070, by mouth</li> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY2880070 inhibits CHK1, which may improve how a tumor responds to a chemotherapy drug. </li> <li class="seamTextUnorderedListItem">Gemcitabine (Gemzar®) is a chemotherapy drug used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">This study will also enroll patients with other types of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02632448' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/druglist/gemzar' target='_blank'>Breastcancer.org: Gemzar</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancercare.org.uk/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/gemcitabine-gemzar#who' target='_blank'>BreastCancerNow.org: Gemzar</a> </li></ul>
107
NEAREST SITE: 2108 miles
Ohio State University
Columbus,OH
VISITS: Visits every 3 weeks, ongoing
PHASE: II
NCT ID: NCT03414684
Carboplatin plus Nivolumab in Advanced Triple Negative Breast Cancer
A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First- or Second-line Metastatic Triple-negative Breast Cancer Scientific Title
Purpose
To compare the safety and effect (good and bad) of giving the chemotherapy drug carboplatin (Paraplatin®) alone or with an immunotherapy drug to treat advanced breast cancer.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-/PR-/HER2-) breast cancer. You may have received up to one prior regimen of chemotherapy for metastatic cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, every 3 weeks, ongoing </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks, ongoing</li></ul>
-
<p class="seamTextPara"> Paraplatin is a chemotherapy drug routinely used to treat advanced breast cancer. </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The immunotherapy drug used in this study is the PD-1 inhibitor nivolumab (Opdivo®). The drug, which has been approved to treat certain types of cancer, but not breast cancer, stimulates the body's immune system to attack cancer cells by blocking a protein called PD-1 (programmed cell death-1).</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03414684' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://triplesteptowardthecure.org/' target='_blank'>Triple Step Toward the Cure</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/publications/cancerwise/2015/04/finding-hope-after-triple-negative-breast-cancer.html' target='_blank'>MDAnderson: Finding Hope After Triple Negative Breast Cancer</a> </li></ul>
108
NEAREST SITE: 2299 miles
Roswell Park Cancer Institute
Buffalo,NY
VISITS: 4 visits over the first 2 weeks, then 1 visit every 3 weeks for 2 years
PHASE: NA
NCT ID: NCT03599453
Chemokine Modulation and Keytruda in Advanced Triple Negative Breast Cancer
Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer Scientific Title
Purpose
To study the safety and effects (good and bad) of using chemokine modulation therapy before treatment with pembrolizumab (Keytruda®).
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) that has not responded to other treatment options.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Celecoxib (Celebrex®), by mouth, twice daily</li> <li class="seamTextUnorderedListItem">Interferon Alfa-2b, by IV, 3 times over 2 weeks </li> <li class="seamTextUnorderedListItem">Rintatolimod, by IV, 3 times over 2 weeks</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, for 2 years</li> <li class="seamTextUnorderedListItem">2 biopsies (before treatment and during treatment)</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Keytruda is a type of immunotherapy drug called a PD-1 (programmed cell death-1) inhibitor. It is approved to treat at least 10 different types of cancer. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Small proteins called chemokines help get the immune cells to specific organs. </li> <li class="seamTextUnorderedListItem">Celecoxib (Celebrex®), recombinant interferon alfa-2b, and rintatolimod (Ampligen) each works in a different way to get chemokines to an organ. </li> <li class="seamTextUnorderedListItem">Chemokine modulation therapy may make Keytruda more effective.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03599453' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rintatolimod' target='_blank'>NCI Drug Dictionary: Rintatolimod</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/recombinant-interferon-alfa-2b' target='_blank'>NCI Drug Dictionary: Interferon Alfa-2b</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/celecoxib' target='_blank'>NCI Drug Dictionary: Celecoxib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pembrolizumab' target='_blank'>NCI Drug Dictionary: Pembrolizumab</a> </li></ul>
109
NEAREST SITE: 2383 miles
Mayo Clinic in Florida
Jacksonville,FL
VISITS: 3 visits a month
PHASE: NA
NCT ID: NCT04249167
Cryoablation, Immunotherapy, & Chemotherapy For Advanced Triple Negative & ER-Low Breast Cancer That Tests Positive For PD-L1
Cryoablation and Anti-PD-L1 Immunotherapy for Triple Negative Breast Cancer (TNBC) Scientific Title
Purpose
To study the safety and effects (good and bad) of cryoablation followed by treatment with atezolizumab (Tecentriq®) and nab-paclitaxel (Abraxane®).
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer whose tumor tests positive for PD-L1.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cryoablation of tumor</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 2 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Nab-paclitaxel (Abraxane®), by IV, every week (3 weeks on, 1 week off), ongoing</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with <span class="highlight">triple</span> <span class="highlight">negative</span> as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Cryoablation uses extreme cold to kill cancer cells. </li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor. It works by blocking the PD-L1 (programmed death-ligand 1) protein.</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is approved for use with the chemotherapy drug Abraxane® to treat advanced, <span class="highlight">triple</span>-<span class="highlight">negative</span>, PD-L1-positive breast cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04249167' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20477447' target='_blank'>Mayo Clinic: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2019/atezolizumab-triple-negative-breast-cancer-fda-approval' target='_blank'>NCI Cancer Currents Blog: Atezolizumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Protein-bound_paclitaxel' target='_blank'>Wikipedia: Protein-bound Paclitaxel</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/issues/october-10-2019/atezolizumab-for-triple-negative-breast-cancer/' target='_blank'>ASCO: Atezolizumab for PD-L1–Positive Locally Advanced or Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.frontiersin.org/articles/10.3389/fimmu.2019.02283/full' target='_blank'>Frontiers in Immunology: Cryoablation and Immunotherapy</a> </li></ul>
110
NEAREST SITE: 2384 miles
Duke University
Durham,NC
VISITS: At least 1 visit every month, ongoing
PHASE: II
NCT ID: NCT03167619
Durvalumab & Olaparib in Advanced Triple Negative Breast Cancer Treated with Chemotherapy
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) Scientific Title
Purpose
To compare the effects (good and bad) of using the targeted therapy olaparib (Lynparza®) alone or with an immunotherapy drug.
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer, already treated with at least four cycles of a platinum-based chemotherapy, and who have had no more than two prior chemotherapies for metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily</li> <li class="seamTextUnorderedListItem">Durvalumab (Imfizi®), by IV, once every month</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lynparza is approved to treat HER2-negative metastatic breast cancer in patients who test positive for an inherited BRCA mutation. </li> <li class="seamTextUnorderedListItem">Lynparza is a PARP inhibitor, a drug that blocks the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA. </li> <li class="seamTextUnorderedListItem">Durvalumab (Imfinzi®) is a type of immunotherapy called a PD-L1 (programmed cell death ligand-1) inhibitor. </li> <li class="seamTextUnorderedListItem">It has been approved to treat certain other types of cancers, and its use in breast cancer is considered experimental.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03167619' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.imfinzi.com/stage-3-nsclc/about/how-imfinzi-works.html?source=imz_c_c_45&umedium=cpc&uadpub=google&ucampaign=2018imfinzidtcnsclcbranded_general&ucreative=branded_alone_ex&uplace=durvalumab&outcome=dtc&cmpid=1' target='_blank'>AstraZeneca Information Page: Imfinzi</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/web-exclusives/durvalumab-improves-survival-in-stage-iii-nsclc' target='_blank'>Oncolive: Durvalumab/Olaparib Combo Is Active in BRCA-Mutated Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
111
NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD
VISITS: 1 visit per month, ongoing
PHASE: II
NCT ID: NCT03394027
ONC201 for Estrogen Receptor Positive or Triple Negative Metastatic Breast Cancer
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Scientific Title
Purpose
To examine the safety and effectiveness of using an experimental drug called ONC201 to slow cancer growth.
Who is this for?
People with estrogen receptor positive or triple negative (ER-, PR- and HER2-) metastatic breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ONC201, by mouth, once a week, ongoing</li> <li class="seamTextUnorderedListItem">Two biopsies, before starting treatment and 5 weeks after</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is also enrolling women with advanced endometrial cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03394027' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://oncoceutics.com/onc201-trial-begins-endometrial-breast-cancer/' target='_blank'>oncoceutics: ONC201 Trial Begins for Endometrial and Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/akt-erk-inhibitor-onc201' target='_blank'>cancer.gov: Akt/ERK inhibitor ONC201</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.eurekalert.org/pub_releases/2018-05/rp-okb050818.php' target='_blank'>EurekAlert: ONC201 kills breast cancer cells in vitro by targeting mitochondria</a> </li></ul>
112
NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda,MD
VISITS: Every 2 weeks for 1 year
PHASE: I-II
NCT ID: NCT02484404
MEDI4736 with Lynparza or Cediranib for Advanced Triple Negative Breast Cancer
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancer Scientific Title
Purpose
To study the safety and effects (good and bad) of giving MEDI4736 and Lynparza together.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer for whom no currently available treatment exists. You must not have received more than three prior therapies for metastatic disease.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> Participants will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEDI4736 (duryalumab), by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MEDI4736 (duryalumab), by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Cediranib, by mouth, daily</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Durvalumab (MEDI4736) is an immunotherapy drug that works by blocking a protein called PD-L1 (programmed cell death ligand-1). Blocking this protein allows the body's immune system to go after cancer cells. </li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a type of cancer drug called a PARP inhibitor. PARP inhibitors interfere with the cancer cells' DNA, making them more sensitive to chemotherapy. </li> <li class="seamTextUnorderedListItem">Lynparza is used to treat advanced ovarian cancer in women who have an inherited BRCA1/2 mutation.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02484404' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=740856' target='_blank'>NCI Drug Dictonary: MEDI4736</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=560191' target='_blank'>NCI Drug Dictonary: Olaparib</a> </li></ul>
113
NEAREST SITE: 2494 miles
Lehigh Valley Health Network
Allentown,PA
VISITS: Number of visits unavailable
PHASE: II
NCT ID: NCT03808337
Stereotactic Body Radiotherapy (SBRT) Combined with Standard of Care Treatment for Metastatic Breast Cancer
A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer Scientific Title
Purpose
To compare the effects (good and bad) of using stereotactic body radiotherapy (SBRT) along with a standard of care treatment to a standard of care treatment alone.
Who is this for?
People with metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-).
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic Body Radiotherapy (SBRT)</li> <li class="seamTextUnorderedListItem">Standard of care determined by your physician</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: </i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care determined by your physician</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SBRT can be used to deliver precise, intense doses of radiation to specific places where the cancer has spread. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of metastatic cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03808337' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/radiotherapy/external/types/stereotactic-body-radiotherapy-sbrt' target='_blank'>CancerResearchUK: Stereotactic Radiotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.uclahealth.org/radonc/faqs-sbrt' target='_blank'>UCLA Health: SBRT FAQs</a> </li></ul>
114
NEAREST SITE: 2539 miles
Memorial Sloan Kettering at Basking Ridge
Basking Ridge,NJ
VISITS: Visits 5 days a week, for 3 weeks
PHASE: II
NCT ID: NCT02422498
Predicting Response to A Combination of Cisplatin & Radiation Therapy in Women with Advanced Triple Negative Breast Cancer
A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy Scientific Title
Purpose
To study if testing a biopsy sample can predict the anti-cancer activity of a combination of the chemotherapy cisplatin and radiation therapy.
Who is this for?
Women with recurrent (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cisplatin (Platinol®), by IV, once a week, for 1-2 weeks</li> <li class="seamTextUnorderedListItem">Followed by radiation therapy, 5 days a week, for 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cisplatin (Platinol®) is a platinum-based chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Radiation therapy can be used to treat cancer cells that have spread to different parts of the body. </li> <li class="seamTextUnorderedListItem">Researchers have developed a test that may predict if your tumor will respond to cisplatin and radiation therapy. </li> <li class="seamTextUnorderedListItem">The test is performed on a biopsy (tissue sample) of the tumor, taken from the breast or elsewhere in the body.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02422498' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/TripleNegativeBreastCancer.html' target='_blank'>Susan G. Komen: Triple Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/radiation/metastatic' target='_blank'>Breastcancer.org: Radiation for Metastatic Breast Cancer</a> </li></ul>
115
NEAREST SITE: 2539 miles
Memoral Sloan Kettering Basking Ridge
Basking Ridge,NJ
VISITS: 1 visit every other day for 6 or 10 days, then visits coincide with standard treatment
PHASE: II
NCT ID: NCT03808662
SBRT Radiation Therapy for Oligoprogressive Metastatic Breast Cancer
A Randomized Phase II Study Assessing the Efficacy of Local Ablative Radiation Therapy for Metastatic Breast and Lung Cancer Patients With Oligoprogressive Disease Scientific Title
Purpose
To evaluate the safety and effects (good and bad) of using stereotactic body radiation therapy (SBRT) to treat each site of metastases.
Who is this for?
People with oligoprogessive metastatic (stage IV)